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( ABSTRACT 
In the pharmaceutical industry, the product and process 
development problems usually involve a number of independent 
variables and are normally characterized by multiple objectives. 
Computer optimization techniques consisting of statistically valid 
experimental design can be employed to provide an economical way 
to obtain efficiently these multiple response parameters. 
Acetaminophen is a poorly compressible analgesic and 
antipyretic drug with high dose level resulting in a corresponding 
very large tablet and poor compactability, the amount of added 
compressible excipient required to produce acceptable compaction 
behavior therefore is increased. Also, most commercially available 
high dose (500 mg) acetaminophen tablets are manufactured from 
slugging or a patented roller-compactor process. In this present 
study, the utility of 50 micron microcrystalline cellulose (Emcocel) as 
a wet granulation excipient in the high dose acetaminophen tablet 
formulation was investigated. A four factor factorial, central, 
composite Box-Wilson experimental design was applied to optimize a 
tablet formulation containing high dose (500 mg) acetaminophen 
(ACMP), Emcocel™, a 50 micron microcrystalline cellulose (MCC), and 
povidone. The percentage of Emcocel™, percentage of povidone, 
amount of granulating water and wet granulation time were used as 
independent variables for optimizing some tablets response 
parameters. Response parameters for final ACMP tablets were 
percentage of ACMP dissolved at fifteen minutes, disintegration time, 
required compression force for producing 8 Kg hardness tablets and 
friability. The data were analyzed by means of quadratic response 
surface models. Response surfaces were generated for tablet 
percentage of dissolution, disintegration time, required compression 
force and friability as a function of independent variables . The 
models were validated for accurate prediction of response 
characteristics and used to indentify the optimum formulation. The 
results suggest that an optimum 500 mg ACMP tablets having a 
volume similar to commercial products made by precompacted ACMP 
can be produced by wet granulation process utilizing 50 micron 
Emcocel™. The tablets made also showed acceptable dissolution 
behavior, hardness, disintegration time and low friability when 
compared to commercially available 500 mg ACMP tablets. 
Additionally , a two factor factorial central, composite Box-Wilson 
experimental design was employed to develop and optimize a novel 
extended release floating and bioadhesive tablet formulation 
containing 240 mg sotalol hydrochloride and polymeric components. 
The ratio of sodium carboxymethylcellulose (N aCMC) to 
hydroxypropylmethylcellulose (HPMC) and the ratio of ethylcellulose 
to crosspovidone were used as formulation variables for optimizing 
some tablets response parameters, such as bioadhesive capability, 
disolution characteristics, tablet density and required compression 
force for producing 6 Kg hardness tablets. The data were also 
analyzed by means of quadratic response surface model. Response 
surfaces were generated as a function of formulation variables. An 
optimum direct compression bioadhesive and floating tablet 
( formulation of sotalol HCl tablet was achieved by considering 
dissolution release characteristic as primary objective and using 
required compression force, bioadhesive capability as constraints 
within the experimental region. The surface model was validated by 
preparing and evaluating the predicted optimum formulation. 
To understand the release mechanism of drug from extended 
release polymeric matrix tablet, the swelling and dissolution 
behavior of different molecular weight PEO (polyethylene oxide) 
polymers rn distilled water at 37 Oc was investigated. Due to the 
swelling of PEO matrix discs, considerable volume expansion was 
observed. Molecular weight is an important determinant of PEO 
dissolution rate, which was inversely proportional to the molecular 
weight of PEO. The results supported the hypothesis that dissolution 
of high molecular weight PEO is controlled by the inward diffusion of 
water and outward diffusion of polymer through the boundary layer. 
The influence of the molecular size and solubility of four tracer 
compounds (phenylpropanolamine HCl, theophylline, sotalol HCI and 
bovine serum albumin) and the effect of the tracer/PEO ratio on the 
dissolution rate in SIF (simulated intestinal fluid) were determined. 
In the process of bioadhesion assessment, an apparatus to be 
equipped with Instron tensile tester was developed to evaluate 
quantitatively the bioadhesive properties of various bioadhesive 
tablets. The equipment was designed to measure the forces required 
to separate two parallel surfaces (tablet and membrane) in both 
horizontal and vertical planes. In this work, in addition to the 
detachment force and adhesion work, the shear force necessary for 
separating bioadhesive tablet and synthetic membrane or biological 
tissue (rabbit stomach mucosa) were also determined since the 
majority of gastrointestinal mocosa surface area possesses some 
elements of tangential shear motion. The effects of different 
quantities and types of bioadhesive polymer on the tablet 
bioadhesive capability were also determined. The results showed 
good agreement with some previous findings that the relative 
adhesion of the tablet formulations was dependent on the 
bioadhesive polymer content. It was also found that tablet made 
with sodium carboxymethycellulose (NaCMC) possessed the best 
bioadhesive power when compared to tablets made with 
polycarbophil and carbopol 974P. 
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PREFACE 
This dissertation is prepared in accordance with the format of the 
"Manuscript Thesis Plan" option described in section 11-3 of the 
Graduate Manual at the University of Rhode Island . . The these is 
divided into four sections. 
Section I consists of a general introduction of the problems and 
objectives of my research. Section II, which is the main body of this 
dissertation comprises four manuscripts which have been written in 
the contemporary format required for publication rn international 
scientific journals. Section III contains a manuscript on the topic of 
bioadhesion assessment which was utilized in our study. Section IV 
consists of three appendices which contain additional information 
and some experimental details not normally included in published 
manuscripts but which are useful background for understanding the 
manuscripts in section II. The bibliography at the end of the 
dissertation cites all the sources and literatures used in writting this 
dissertation. 
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SECTION I 
1 
( INTRODUCTION 
For many years, pharmaceutical formulation scientists have used 
knowledge derived from individual expenence to develop 
pharmaceutical dosage forms. The development of formulation and 
process are mostly based on intuitive and subjective judgement 
rather than a rational operation, therefore the whole process may or 
may not be optimal. Often formulation scientists are. challenged with 
the problems of producing a final product which meets not only the 
requirements placed on it from a bioavailability standpoint, but also 
the practical mass production criteria of process and product 
reproducibility with limited time and funds. Trial and error 
approaches are inefficient and costly, and extrapolations made from 
them can be inaccurate. Stringent federal regulations, such as those 
promulgated by the Food and Drug Administration (FDA), require 
production process to be well-characterized and validated. In 
addition, during the development of a drug product for New Drug 
Application (NDA) submission, it is necessary to characterize the 
performance of the product during the process and to demonstrate 
that the final dosage form will behave in a predictable manner. 
Optimization techniques consisting of statistically valid 
experimental design were originated m the mathematics and 
chemical engineering fields ( 1) to provide an economical way to 
obtain efficiently the most information while expending the least 
amount of experimental effort. Although optimization techniques 
have been utilized on some pharmaceutical formulation development 
2 
processes (2-5), the major emphasis in these studies was the 
optimization of conventional dosage forms. However, there appears 
to be little published data which demonstrates the application of 
optimization processes to difficult formulation tasks such as the high 
dose acetaminophen - microcrystalline cellulose (MCC) (6-9) wet 
granulation process. When dealing with the manufacturing high dose 
tablets by means of a low shear mixing and wet granulating 
technique, there are many formulation and process variables may 
affect the physical properties of the final tablet, especially;._) 
acetaminophen is a brittle, poorly compressible analgesic and 
antipyretic agent with high dose level, resulting in a corresponding 
very large tablet and poor compressibility, the amount of added 
excipient (MCC) required to produce acceptable compaction behavior 
is increased. The ratio of ACMP to MCC and some other process 
variables are required to be optimized to produce an acceptable 
tablet volume and physical properties. Meanwhile, most commercial 
tablets containing 500 mg acetaminophen are produced from 
slugging or pre-compacted granulation by variation on a patented 
roller-compactor process (10) and these newly formulated products 
would have to undergo bioavailability, stability and possibly even 
safety studies. 
Also, in the pharmaceutical industry there is an increasing 
interest in the development and utilization of extended-release drug 
delivery systems. Oral sustained release dosage forms have received 
a great deal of attention, since they are the most convenient to 
administer. Nevertheless, the published literature also is devoid of 
3 
( 
( 
( 
quantitative data illustrating the utility of optimization techniques to 
extended-release solid dosage forms (to control extended release 
characteristic (dissolution behavior) as a function of time and pH of 
the dissolution medium) (11, 12), I hypothesized that an efficient 
optimization technique utilizing Response Surface Methodology can 
be used not only to develop a conventional high dose 
acetaminophen-MCC wet granulated tablet formulation which would 
possess suitable physical properties but also to develop an improved 
extended-release sotalol solid dosage formulation which would retain 
the active in the upper part of gastrointestinal tract for a satisfactory 
time so as to exhibit acceptable in vitro dissolution rate and 
satisfactory in vivo bioavailability. Sotalol is a drug which appears to 
have absorption from the gastrointestinal tract limited to the upper 
part of the small intestine, thus it is desirable that an extended 
release drug delivery system should possess the ability to remain for 
long periods in the stomach. &1n recent y.ears, there have emerged 
two comprehensive approaches for enhancing the drug residence 
time rn the stomach, floatation and bioadhesion drug delivery 
systems. However, the ability of a floating drug delivery systems to 
remain in the stomach is distinctly limited as the stomach empties 
almost completely at quite short intervals. Similarly the efficiency of 
a bioadhesive drug delivery system will be adversely affected when 
the stomach is full and semi-liquid contents are churning around 
under the influence of peristaltic movement. Thus a system which 
and adhesive properties would give a uniquely 
valuable ability to remain in the stomach. The review of published 
.... 
literature indicates that there is no drug delivery system which 
4 
{ possesses a combination of floatation and adhesion characteristics to 
prolong residence time in the stomach. It was my intention to 
develop a novel drug delivery system which is both bioadhesive and 
capable of floatation to remain in the stomach for a longer period of 
time and to have an extented release of sotalol from the the delivery 
system. 
The application of an optimization technique consisting of 
statistically valid experimental design to pharmaceutical formulation 
development would provide an efficient and economical method to 
acquue the necessary information to understand the relationship 
between controllable (independent) variables and performance or 
quality (dependent) variables (13 ). The optimization process 
provides not only efficient use of resources, but also a method to 
obtain a mathematical model which can be used to characterize and 
optimize a formulation or process. Furthermore, by accurately 
defining the whole system, optimization techniques are a useful aid 
to process validation. 
The wet granulation process has been used as an alternative for 
high dose and poorly compressible active ingredients. It offers 
several advantages over other methods, for instance, it improves 
flowability, resistance to segregaion and compression characteristics 
by increasing the particle size and cohesion (14 ). Acetaminophen is a 
drug which requires a high dose, thus resulting in a large tablet. 
Since the drug also has poor compactability, the amount of added 
excipient (MCC) required to produce acceptable compaction behavior 
5 
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must be very completely controlled. However, during the wet 
granulation process, there are many process and formulation 
variables which will affect the physical properties of the granules 
and of the final tablets (15). As the number of independent 
variables increase, the number of experiments required to evaluate 
the effect of different levels of each variable will be increased 
substantially. With optimization studies, one is able to obtain the 
most information with the least amount of experimental effort. 
Some physical-chemical properties and limited pharmacokinetic 
data pertaining to conventional sotalol dosage form have been 
reported in literature ( 16-19). The effect of formulation and process 
variables on the physical properties of sotalol tablets such as release 
characteristic of sotalol, hardness, friability and compaction 
characteristic have to be determined. With the application of this 
optimization technique, it 1s believed that it is possible to develop a 
cost effective conventional acetaminophen tablet formulation and 
also to develop an improved extended release formulation of sotalol 
with enhanced release characteristic, physical and chemical stability. 
The specific objectives of this research were: 
1. To investigate the utility of 50 micron microcrystalline cellulose 
(Emcocel™) as an excipient in the high dose(500 mg) acetaminophen 
tablets made by conventional wet granulation process. 
2. To address the characterization and optimization of 500 mg 
acetaminophen wet granulation tablets by using statistical respone 
6 
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surface experimental design, an instrumented low shear planetary 
Hobart mixer and an instrumented rotary tablet press. 
3. To develop an extended release, floating and bioadhesive tablet by 
usrng computer optimization techniques employing response surface 
methdology. 
4. To study the release mechanisms of different drugs from 
swellable and erodible hydrophilic polymers by characterizing the 
swelling and erosion processes of polymers. 
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MANUSCRIPT I 
OPTIMIZATION OF A HIGH DOSE (500 MG) ACETAMINOPHEN-
MICROCRYSTALLINE CELLULOSE TABLET 
H. R. Chueh, D. W. Woodford and C. T. Rhodes 
University of Rhode Island, Department of Pharmaceutics, 
Kingston, RI 02881 
ABSTRACT 
A four factor factorial, central, composite Box-Wilson 
experimental design was applied to optimize a tablet formulation 
containing high dose (500 mg) acetaminophen (ACMP), Emcocel™, a 
50 micron microcrystalline cellulose (MCC), and povidone. The 
percentage of EmcocelT M, percentage of povidone, amount of 
granulating water and wet granulation time were used as 
independent variables for optimizing some tablets response 
parameters. Response parameters for final ACMP tablets were 
percentage of ACMP dissolved at fifteen minutes, disintegration time, 
required compression force for producing 8 Kg hardness tablets and 
friability. The data were analyzed by means of quadratic response 
surface models. Response surfaces were generated for tablet 
percentage of dissolution, disintegration time, required compression 
force and friability as a function of independent variables. The 
models were validated for accurate prediction of response 
characteristics and used to indentify the optimum formulation. The 
1 0 
results suggest that an optimum 500 mg ACMP tablets having a 
volume similar to commercial products made by precompacted ACMP 
can be produced by wet granulation process utilizing 50 micron 
Emcocel. The tablets made also showed acceptable dissolution 
behavior, hardness, disintegration time and low friability when 
compared to commercially available 500 mg ACMP tablets. 
INTRODUCTION 
Optimization of product {)TO 
engineering field ( 1 ). 
originated within the chemical 
and comprehensive approach for 
pharmaceutical use in situations involving more than two variables 
was reported (2) that requires minimal familiarity with computer 
programming or optimization mathematics. Through the process of 
optimization, the researcher may discover solutions to formulation 
challenges which would otherwise be dismissed as unrealistic. The 
technique has been extended to obtain some desirable pharmaceutics 
and pharmacokinetic parameters by variation of formulation and 
process parameters (3-7). 
Standard formulation methods often involve running a grid 
search about a formulation or process starting point. The initial point 
is either an educated guess or deduced from prior art. Such grid 
searches are expensive in terms of time, labor and materials, and 
also may result in a missed solution to the problem. One reason for 
the existence of serendipitous solutions is illustrated by the analogy 
1 1 
of the effects of higher order harmonics produced by constructive 
from the interaction of two or more fundamental frequencies. 
Similarly, either the concentrations of two or more ingredients, or the 
levels of two or more processing parameters may interact to produce 
an unanticipated result. This is sometimes refered to as synergism 
or potentiation, in which the effect of supposedly independent 
factors is many fold the sum of effects of the factors taken 
separately. Thus, some factors may be dis.covered to be 
interdependent. Utilizing the tool of optimization, workers have 
developed and marketed a tablet formulation containing 800 mg of 
ibuprofen, a poorly compactable material-me! · 
tablet with a minimum of excipient (8). This made possible the 
manufacture of a tablet of palatable dimensions and acceptable 
hardness, friability and dissolution performance. 
A second advantage obtained when using optimization is the 
substantial time and cost savings due to the inherent efficiency of a 
rational experimental design (9). No theoretical model is required to 
be followed in advance of experimentation, curve fitting yields an 
empirical function. Subsequently, that function can be used to 
extrapolate results from those obtained at nodes in the experimental 
matrix to predict outcomes at points between the nodes, This allows 
one to draw tentative conclusions for hypothetical experiments, so 
that it may not be necessary to perform the actual experiment unless 
the prediction is favorable. One computer package called X-Stat (John 
Wiley and Sons) includes experimental design, data entry 
spreadsheets, curve fitting by various functions and contour plotting 
1 2 
of results. Using contour plots, the effects of multiple factors may be 
viewed simultaneously and conclusions drawn. 
In this present study, acetaminophen was selected as a model 
drug because it requires a high dose (500 mg), resulting m a 
correspondingly large tablet. Since this drug also has poor 
compactability, the amount of added excipient, microcrystalline 
cellulose, required to produce acceptable compaction behavior is 
increased (10-13), the ratio of ACMP to Emcocel™ and some process 
variables are required to be optimized to produce an acceptable 
tablet volume and physical properties. Also, most commercial tablets 
containing 500 mg acetaminophen are produced from pre-compacted 
granulation by variation on a patented roller-compactor process. 
This work shows the attributes of tablets made by an alternative 
densification process, wet granulation. 50 micron MCC, as opposed to 
90 micron MCC, is similar in particle size to the ACMP powder, which 
is expected to improve mixing in the manufacturing process and 
wettability in the disintegration process. 
EXPERIMENTAL 
Wet Granulation 
1. Dry Blending - The total weight of both acetaminophen (Ruger 
Chemical Co., Lot# R36192B 15) and Microcrystalline cellulose 
(Emcocel™, Edward Mendell Co., Lot # 3210X) was held constant at 
300 grams for all experiments. Acetaminophen(ACMP) was weighed 
out and placed into the bowl, Emcocel™ was weighed out and added 
1 3 
on top of the ACMP. The teflon-coated planetary mixer blade was of 
the cardioid (anchor) type, the blade was run at 64 rpm for ten 
minutes to acheive dry blending. At ten minute mark, binder 
(povidone solution) addition was initiated. The pre-dissolved 
povidone aqueous binder solution was added by peristaltic pump to 
the powder blend with continuous mixing at 64 rpm. During the 
course of each experiment, the binder addition rate was constant, as 
determined by timing the fill rate of a graduated cylinder. Because 
of the experimental design, the total volume of granulation fluid for 
each batch was required to be delivered over a different length of 
time. Consequently, the corresponding flow rate for different 
batches ranged from 6 to 20 grams/minute. The m1xrng was 
continued for one minute longer after the binder liquid addition was 
completed m order to assure a homogeneous distribution of the last 
portion of binder solution. 
2. Wet Screening- The granulated mass was gently hand-screeneed 
through a #6 mesh sieve. 
3. Drying- A calibrated crossflow oven was used for drying at 45 oc. 
The crossflow air was controlled at 1.3 L/sec. Custom-made 
retangular drying trays, sized 14 cm by 24 cm, were lined with 
heavy aluminum foil, the exposed surface area of 200 cm2 at a 
constant bed depth of 3 cm. Drying was halted when a full-thickness 
sample produced an L.O.D. (Loss On Drying) of 1.0 +/- 0.2 %. The 
L.O.D. test utilized 10 grams of sample triturated to pass a 20 mesh 
sccreen, with the lamp set at five watts for ten minutes. 
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4. Dry Screening- Dried granules were gently hand-screened through 
a 12 mesh screen, selected to suit the 0.47 inch flat face punch 
diameter, for tablet manufacture. 
Tab letting 
1. Lubrication- Granulations were lubricated with 0.5 % of 
magnesium stearate. The lubricant was hand-screened through a 40 
mesh sieve, then added on top of the granulation m the mixing 
container. Mixing was continued for five minutes in a Turbular 
blender. 
2. Compaction- Tablets were compressed on an instrumented Stoke 
B-2 rotary press at 30 rpm. Tablet weight was adjusted to obtain 
500 mg of active ingredient. Tablet press pressure was adjusted to 
obtain 8 kg hardness tablets, the required compression force was 
measured by the piezoelectric force transducer located in the 
eyebolt. The analog data from the piezoelectric force transducer 
were converted to the digital form by the analog to the digital 
converter. The digital output was then collected and analyzed on 
personal computer. 
Tablet Evaluation 
1. In vitro Dissolution- The USP Method II (paddle method) was 
used and six tablets were tested for each batch. The dissolution 
medium was 900 ml of pH 5.8 phosphate buffer solution equilibrated 
at 37 °C and stirred at 50 rpm. The dissolution medium volume was 
kept constant by adding the same volume of fresh dissolution 
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medium kept at the temperature of 37 °C. Additionally, to ensure 
total release of drug , the agitation speed was increased to 150 rpm 
for additional 30 minute. The dissolution samples were diluted and 
the concentration were determined on a Diode Array 
Spectrophotometer(Hewlett Packard) at the wavelength of 243 nm as 
specified in the USP. The mean percentage dissolved was calculated 
at the fifteen minute sampling point. 
2. Disintegration Time- Disintegration time was measured m a USP 
disintegration time tester with disc (Vanderkamp; Van-Kel 
industries) in 0.1 N HCl at 37 oc. Six tablets were evaluated for 
disintegration time. 
3. Friability and Hardness- Twenty tablets were evaluated for 
friability by a Roche friabilator at 25 rpm for four minutes (100 
drops). Ten tablets were measured for hardness from Erweka 
hardness tester. 
Experimental Design 
The four independent variables and their ranges selected for wet 
granulation process were summarized in Table I, X 1 represents the 
percentage of EmcocelT M, X2 is percentage (w/w) of binder, X3 
represents amount of granulating water and X4 represents the total 
granulation time. All other processing and formulation variables 
remained constant throughout the study. Table II listed a total of 31 
experiments required in a four factor factorial, central, composite 
Box-Wilson experimental design (14). This design is based on 
1 6 
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factorial design with additional points added to estimate curvature of 
the response surface. As shown in Table II, the first sixteen 
experiments represent a half-factorial design for four factors at two 
levels, these two levels are represented by + 1 and -1, analogous to 
the high and low values in any two level factorial design. For the 
remarnrng formulations, three additional levels were selected. The 
zero level represents a center point midway between the + 1 and -1 
and the levels noted as +2 and -2 represent axial point at extreme 
values. The design also includes seven replicate of center points, this 
allows a lack-of-fit test for the mathematical model, because 
standard designs with fewer trials would have resulted in 
confounding among model terms and increased the risk of inaccurate 
conclusion. 
The translation of the statistical design into physical units for the 
four independent variables is shown in Table III. Table IV 
summarizes the response parameters 
tablets. These parameters are Y 1, 
measured on the resulting 
mean percentage of drug 
dissolved at fifteen minute sampling point; Y2, disintegration time; 
Y3, friability and Y 4, required compresion force for producing 8 kg 
hardness tablets. 
Analysis of Data 
All the statistical and regress10n analysis procedures on the 
response parameters were performed using the X-STAT software 
package. Statistical Analysis was carried out which includes the 
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calculation of mean values for each of the four response parameters 
in each of 31 experiments. 
The sets of data obtaining from the statistical analysis were then 
subjected to computerized regression analysis to determine the fit to 
a second-order model. These regression models include an intercept 
and marn effect terms of each independent variable, two-way 
interaction terms and second order effect terms as shown in Table V. 
A stepwise regression procedure was used to assess all main effects, 
some two-way interactions and quadratic terms for usefulness in the 
model to obtain a more adequate regression model for each response 
parameter (15-16). 
RESULTS AND DISCUSSION 
Table VI summanzes the response tablet · properties obtained 
from the 31 formulations in experimental design. The percentage of 
ACMP dissolved at fifteen minutes ranged from 17 .3 to 100%, tablet 
disintegration time ranged from 0.4 to 55 minutes, the required 
compression force ranged from 9.3 to 28 KN when friability of tablets 
ranged from 0.2 to 12.4%. For each response property, some 
variations were observed among formulations. 
Table VII to X show the particular model for each of response 
parameter, these Tables also include computer regression coefficient 
for each term in the regression model. As can be seen, most of these 
standard error values are less than 50% of the absolute values of 
1 8 
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their regress10n coefficients. These results indicate the adequacy of 
the models, also, the high values of confidence level indicate that 
these variable terms have standard significant effects on the 
response parameter. Although, there are few terms which do not 
contribute significantly at 90% confidence level to the model, 
however, these terms, as a group, do affect the shape of the contour 
plot. As shown in Table XI, after selecting a modified quadratic 
model for each response parameter, the F ratio for lack of fit was 
decreased when compared to F ratio of general quadratic model and 
smaller than the critical F ratio for significant lack of fit. It indicates 
that the lack of fit for each model is statistically insignificant at a 90 
to 95% confidence limit which means these postulated models are 
adequate for fitting data. Meanwhile, the high multiple correlation 
coefficient values of each response parameter denote the adequacy 
of these models. It implies that the regression equation explains 
large portion of variation of response parameter about its mean. In 
Table XI, the high F ratios of regression indicate that many model 
terms are important for explaining variability, it also reveals 99% 
confidence regression equation is non-zero. 
For each response parameter, the multiple correlation coefficient 
was greater than 0.91 indicating that there are at least more than 
91 % of the total variations observed in the response parameter could 
be explained as being caused by the independent variables in the 
way described by the equation as shown in Table VII to X. Also, the 
predicted minimum and maximum values for each response 
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parameter show good agreement with the experimental results 
obtained from 31 batches shown in Table VI. 
Contour plots for each of response parameters were generated 
using selected quadratic response surface model. Figure 1 show the 
effect of Emcocel™ and povidone on tablet dissolution (% of drug 
released at fifteen minutes sampling point). As can be seen, the 
percentage of dissolution decreased with the increasing percentage of 
povidone as percentage of Emcocel™ decreased when the amount of 
granulating water and granulation time were held at constant values. 
This is due to the increased disintegration time. As shown in Figure 
2, it demonstrates that the tablet disintegration time increased with 
increasing percentage of povidone as percentage of EmcocelT M 
decreased. Tablet formulation containing 25 % of Emcocel™, 1 % of 
povidone and granulated with 94 gram water rn eight minutes gives 
the shortest disintegration time. 
In Figure 3, the required compress10n force decreased with 
increasing amount of granulating water as percentage of povidone 
increased. Figures 4 and 5 indicate that a formulation containing 
25% of Emcocel, 4.4% of povidone and granulated with 112 gm water 
m 10 minutes would require the lowest compression force to produce 
8 kg hardness tablet. Without sufficient granulation time, 
formulation containing high percentage of povidone would increase 
the required compression force in tablet manufacturing process, this 
is attributed to those hard and dense granules generated from 
improper distribution of high concentration of binder solution in the 
20 
mixing process. These too hard and dense granules do not 
consolidate very well under low compression force. 
Figure 6 demonstrates the effect of Emcocel™ and granulating 
water on the tablet friability. It indicates when there IS more 
Emcocel in the fromulation, the more granulating water are required 
to agglomerate and produce less friable tablets. Figures 7 to 13 also 
show the relationship between the response parameter and the 
independent variables. These Figures illustrate contour line of equal 
response and the direction in which the gradient has steeper values. 
The optimum values obtained from the contour plots for the 
independent variables in order to obtain the best values for each of 
the four response variables are given in Table XII. The optimum 
level of Emcocel™ for maximum percentage of dissolution and 
minimum required compression force is 25% when the optimum 
level of Emcocel for the shortest disintegration time and the lowest 
friability is 21 % . The optimum level of povidone for % dissolution 
and disintegration time is 1 %, however, the optimum values for 
friability and required compression force are 5.8 and 4.4 %, 
respectively. A range of 94 gm to 120 gm granulating water is 
required for obtaining the best results of each of response 
parameters. 
minutes. 
The optimum range of granulation time is 8 to 10 
Since in vitro dissolution data may provide an indication of in 
VIVO bioavailability, therefore, the percentage of drug dissolved at 20 
2 1 
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minutes was identified as the response parameter of pnmary 
concern. It was maximized so as to obtain the fastest dissolution 
rate. As shown in Table XIII, the constraints used for obtaining the 
fastest dissolution were that disintegration time should be greater 
than 0.3 minute, the friability should be less than 0.8% and the 
required compression force should be less than 14 KN. Additional 
constraints were the experimental range limits placed on values of 
all independent variables. The optimum formulat~on satisfied all 
constraints simultaneously and provided an optimal value for the 
primary function, rapid dissolution. 
The formulation according to the optimal solution was prepared 
as shown in Table XIII and tablets were manufactured on the rotary 
press, tablets properties were also determined. The comparison of 
predicted and experimental values for optimum formulation showed 
very good agreement and are shown in Table XIV. A model is valid 
despite its inexactness in representing the system, it can give a 
reasonable prediction of a system performance. 
The optimized 500 mg ACMP tablets were compared with some 
commercially available 500 mg ACMP tablets in terms of dissolution, 
disintegration time, hardness, friability, weight and volume. As 
shown in Table XV, the optimized tablets made without any 
disintegrant exhibit satisfactory and comparable dissolution 
characteristics. The disintegration time of optimized tablets is even 
shorter than two of commercial tablets. Tylenol tablets possess the 
lowest friability. Although the optimized tablets have the highest 
22 
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tablet weight, however, due to the higher density of the granules, the 
tablet volume is very similar to the commercial tablets. 
CONCLUSIONS 
By usmg computer optimization process, with some constraints on 
other tablets properties, 300 gm formulation batch containing 25% of 
Emcocel™, 1 % of povidone in 120 gm granulating water, granulated 
in 9 minutes was found to be able to produce 500 mg ACMP tablet~ 
which possess the best dissolution characteristic, about 95% of drug 
dissolved at 15 minute sampling time. These tablets also exhibit fast 
disintegration time, 30 seconds, even without any disintegrant in the 
tablet, 8 kg hardness, 0.3% friability, 9 KN required compression 
force for producing tablets and very comparable tablet volume with 
commercially available 500 mg ACMP tablets. The wet granulation 
process utilizing Emcocel™ as an excipient to densification seems to 
be a feasible alternative to the dry compaction approach for 
producing 500 mg acetaminophen tablet. The expensive drying 
process of wet granulation process may be offset by saving in 
starting material costs and in omission of the slugging or roller 
compaction steps used in dry processing. 
In this high dose ACMP tablet formulation development, 
computer-assisted regression analysis and mathematic model can be 
utilized to produce accurate representation of the relationship 
between the independent variables and tablets response properties 
23 
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and optimize a suitable tablet formulation. The optimization 
technique can help us to further define and control the whole 
system. 
The predicted values of response tablet properties of the 
optimum ACMP tablet formulation show good agreement with the 
experimental results. These ACMP tablets could be produced at 
rather low compression force to show very comparable dissolution 
characteristic, disintegration time, hardness, friability and volume 
with some commercially available tablets. 
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TABLE 1--- SUMMARY OF IN-PROCESS VARIABLES USED IN THE 
OPTIMIZATION STUDY 
IN-PROCESS VARIABLES RANGE 
X 1: Intragranular Emcocel % 5% - 25% 
X2: Povidone % 1% - 9% 
X3: Granulating Water, gm 40gm - 120 gm 
X4: Granulation Time, minutes 2.5 -12.5 min. 
26 
TABLE II-- BOX-WILSON EXPERIMENTAL DESlGN FOR FOUR FACTORS 
BATCH# Xl X2 X3 X4 
~-----~--------------------------------------------------~----~-
1 - 1 - 1 - 1 - 1 
2 1 - 1 - 1 - 1 
3 - 1 1 - 1 - 1 
4 1 1 - 1 - 1 
5 - 1 - 1 1 - 1 
6 1 - 1 1 - 1 
7 - 1 1 1 - 1 
8 1 1 1 - 1 
9 - 1 - 1 - 1 1 
10 1 - 1 - 1 1 
1 l - 1 1 - 1 1 
12 1 1 - 1 1 
13 - 1 - 1 1 1 
14 1 - 1 1 1 
15 - 1 1 1 1 
16 1 1 1 1 
17 -2 0 0 0 
18 2 0 0 0 
19 0 -2 0 0 
( 20 0 2 0 0 
21 0 0 -2 0 
22 0 0 2 0 
23 0 0 0 -2 
24 0 0 0 2 
25 0 0 0 0 
26 0 0 0 0 
27 0 0 0 0 
28 0 0 0 0 
29 0 0 0 0 
30 0 0 0 0 
31 0 0 0 0 
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Table III --- TRANSLATION OF EXPERLMENTAL CONDITIONS 
-2 - 1 0 1 2 
FACTORS: 
X 1 = Emcocel™ % 5 1 0 1 5 20 25 
* eu : 5 % 
X2 = Binder (PVP) % 1 3 5 7 9 
eu: 2 % 
X3 = Water mass (gm) 40 60 80 100 120 
eu: 20 gm 
X4 = Granulation time (min.) 2.5 5 7.5 1 0 12.5 
eu: 2.5 min. 
* eu: experimental unit 
28 
TABLE IV -- SUMMARY OF RESPONSE PARAMETERS USED IN THE 
OPTIMIZATION STUDY 
RESPONSE PARAMETERS 
Yl: Dissolution, % (% Released at 15 minutes) 
Y2: Disintegration Time, minutes 
Y3: Friability, % 
Y 4: Required Compression Force, KN 
29 
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TABLE V: 
General Quadratic Response Surface Model: 
y = bo + b1X1 + b2X2 + b3X3 + b4X4 + 
bsX1 X2 + b5X1 X3 + b7X1 X4 + baX2X3 + 
2 2 
b9X2X4 + b10X3X4 + b11X1 + b12X2 + 
2 2 
b13X3 + b14X4 
( TABLE VI -- SUMMARY OF TABLETS PROPERTIES 
Batch# Dissolution Disintegration Compression Friability 
(%) Time (min.) Force (KN) (%) 
1 39.6 1.5 26 6.4 
2 79.2 0.4 28 12.4 
3 27.2 48 25 0.8 
4 17.3 36 22 2.2 
5 45 8 15 0.4 
6 100 0.8 9 .3 0.7 
7 23.8 40 12 0.4 
8 24.7 30 14.5 0.4 
9 57.6 3 28 5.4 
10 62 0.8 26 10.2 
11 27.4 55 15.4 0.6 
12 21.2 43 20 0.5 
13 62.2 4 13 0 .9 
14 95 l 10.2 0.7 
15 29 .5 25 11.3 0.4 
16 23.7 16 11.4 0.4 
17 27 . 1 21 11.2 0 .6 
l 8 93.6 5 9.7 0.7 
19 76.6 0.5 17 .5 2.1 
( 20 25.2 42 10.2 0.2 
21 NA NA NA NA 
22 44.4 8 11.3 0.8 
23 35.2 12 13.3 0.9 
24 28.8 12 11.6 0.7 
25 28 .2 12 12 .0 0.6 
26 35.2 12.5 11.7 0.5 
27 36.1 12.5 12.3 0.6 
28 36.8 12 11.9 0.7 
29 35.6 12 11. 7 0.6 
30 37.3 13 12.5 0.6 
31 36.1 12.5 11.8 0.7 
Range 17.3 - 100 % 0.4 - 55 min. 9.3 - 28 KN 0.2 - 12.4 % 
3 1 
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TABLE VII- Regression Coefficients for DISSOLUTION 
---------------------------------------
---------------------------------------
Standard Confidence 
Coefficient Term Error T-Value Coef <> 0 
38.40 1.000 12.34 3.111 99.7% 
-0.4680 EMCOCEL 0.7847 0.5964 43.4% 
w -2.036 POV I DONE 1.885 1.080 69.0% 
N 0.09386 WATER 0.1254 0.7485 51.8% 
0.07483 RUNTIME 0.3808 0.1965 23.4% 
-0.2387 (EMCOCEL*POVIDONE) 0.0583 4.094 99.9% 
0.008591 (EMCOCEL*WATER) 0.0058 1.473 84.2% 
-0.02157 (POVIDONE*WATER) 0.0146 1.480 84.4% 
0.06634 (EMCOCEL*EMCOCEL) 0.0175 3.782 99.9% 
0.2670 (POVIDONE*POVIDONE) 0.1096 2.435 98.3% 
Confidence figures are based on 20 degrees of freedom 
-TABLE VIII - Regression Coefficients for DISINTEGRATION 
------------------------------------------
------------------------------------------
Standard Confidence 
Coefficient Tera Error T-Value Coef <> 0 
0.3235 1.000 8.516 0.0380 17.2% 
-0.1389 EllCOCEL 0.1946 0.7137 49.9% 
5.024 POV I DONE 1.051 4.780 99.9% 
-0.1210 WATER 0.1561 0.7754 53.2% 
1.075 RUNTIME 0.5631 1.909 93.1% 
-0.0460% (EllCOCEL•POVIDONE) 0.0326 1.412 82.3% 
w -0.03092 (POVIDONE•WATER) 0.0081 3.796 99.9% 
w -0.01520 (WATER•RUNTIME) 0.0065 2.333 97.8% 
0.1854 (POVIDONE•POVIDONE) 0.0609 3.045 99.6% 
0.001708 (WATER•WATER) 0.0008 2.121 96.2% 
Confidence figures are based on 20 degrees of freedoa 
TABLE IX - Regression Coefficients for COMPRESSION 
---------------------------------------
Standard Confidence 
Coefficient Ter• Error T-Value Coef <> 0 
145.3 1.000 13.00 11.17 99.9% 
-0.5408 EMCOCEL 0.2889 1.872 93.1% 
-7.603 POV I DONE 1.919 3.963 99.9% 
-2.216 WATER 0.2376 9.327 99.9% 
-1.493 RUNTIME 1.148 1.301 78.3% 
V.> 0.09250 (EMCOCEL*POVIDONE) 0.0549 1.684 89.6% 
~ 0.04594 (POVIDONE*WATER) 0.0137 3.346 99.8% 
-0.1525 (POVIDONE*RUNTIME) 0.1098 1.388 81.4% 
0.2842 (POVIDONE*POVIDONE) 0.1033 2.752 99.2% 
0.01040 (WATER*WATER) 0.0014 7.674 99.9% 
0.1259 (RUNTIME*RUNTIME) 0.0661 1. 905 93.6% 
Confidence figures are based on 19 degrees of freedo• 
TABLE X - Regression Coefficients for FRIABILITY 
--------------------------------------
--------------------------------------
Standard Confidence 
Coefficient Ter• Error T-Value Coef <> 0 
24.45 1.000 3.105 7.874 99.9% 
0.4749 EMCOCEL 0.1078 4.406 99.9% 
-2.075 POV I DONE 0.3483 5.957 99.9% 
-0.3698 WATER 0.0542 6.823 99.9% 
v.> 
-0.4483 RUNTIME 0.1866 2.403 98.0% Vt 
-0.02516 (EMCOCEL*POVIDONE) 0.0108 2.330 97.7% 
-0.003234 (EMCOCEL*WATER) 0.0011 2.996 99.5% 
0.01754 (POVIDONE*WATER) 0.0027 6.498 99.9% 
0.004281 (WATER•RUNTIME) 0.0022 1.983 94.6% 
0.04124 (POVIDONE*POVIDONE) 0.0202 2.045 95.4% 
0.001294 (WATER*WATER) 0.0003 4.856 99.9% 
Confidence figures are based on 19 degrees of freedom 
( TABLE XI -- REGRESSION SUMMARY AND PREDICI'ED RESPONSE 
PARAMETERS RANGES 
F-rario Response 
Parameter Regression Lack of Fit 
Dissolution 18.6la 2.80 < F0.05 , 14,6 
Disintegration 28 .33a 3.23 < F0.05, 14,6 
Fri ability 15 .82a 4.47 < F0.025,13.6 
Compression 2 l.68a 2.66<F0.05,13,6 
Force 
a: significant at 1 % 
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Predicted Values 
Min. Max . 
0.92 18.4 95.6 
0.93 0 .3 50 .4 
0 .92 0 . 1 10 
0.92 7.9 28.3 
( TABLE XII -- OPTIMUM VALUES OF INDEPENDENT VARIABLES TO OBTAIN BEST POSSIBLE RESPONSE PARA.METERS 
Factors 
Emcocel % 
Povidone % 
Granulating 
water (gm ) 
Granulation 
Time (min .) 
Dissolution 
Disintegration 
Friability 
Response Parameters 
Dissolution ( % ) Disintegration Friability 
Time (min. ) (%) 
25 % 21. l % 21 % 
1 % 1.27 % 5.77 % 
120 gm 94 gm 101 gm 
9 .3 min. 8 min . 10 min. 
2S.!i % 73 .3 % 42 % 
0.3 min . !l .1 min. 9 .5 min . 
0.26 % 1.8 % !l.1 % 
Compression Force 8.54 KN 10.5 KN 8.31 KN 
37 
Compression 
Force (KN) 
25 % 
4.4 % 
112 gm 
10 min . 
62.8 % 
3.8 min . 
0.1 % 
Z.2J K~ 
( TABLE XIII--- CHOICE OF OPTIMUM FORMULATION 
Independent Variable 
X 1: Intragranular Emcocel % 
X2: Povidone % 
X3: Amount of granulating water 
X4: Granulation time 
Value 
25 % 
1% 
120 gm 
9 minutes 
Constrain ts: 1. Disintegration Time > 0.3 minutes 
2. Friability < 0.8 % 
3. Compression Force < 14 KN 
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( TABLE XIV-- COMPARISON OF PREDICfED AND EXPERIMENTAL 
VALUES OF RESPONSE VARIABLE FOR OPTIMUM 
FORMULATION 
Dissolution Disintegration Friability Compression 
(%) Time (min.) (%) Force (KN) 
Constraint > 0.3 min. <0.8 % < l4KN 
Predicted 95.6 % 0.3 mm. 0.26 % 8.54 KN 
Experimental 94.3 % 0.5 min. 0.31 % 9.14 KN 
(2.1 %) (0.2 min.) (1.2 KN) 
Values in parenthesis are standard deviations. 
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TABLE XV-- THE PROPERTIES OF VARIOUS ACETAMINOPHEN 
(500mg) TABLETS 
Dissolution 
(% at 15 min.) 
Disintegration 
(minute) 
Hardness (Kg) 
Friability (%) 
Weight (mg) 
Volume (cm3) 
ACMP-Emcocel™ Tylenol(XS) Panadol Datril 
95.6(2.1) 99.8(1.8) 98.7(2.3) 98.5(2 .5) 
0.5 (0.2) 0.5 (0.1) 2.5 (0.2) 3 .5 (0.3) 
8.5 (0.6) 9 (0.5) 10.3 (0.6) 9.5 (0.5) 
0.31 0.15 0.25 0.34 
660 632 640 625 
0.56 0.56 0.55 0.52 
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1. Introduction 
Oral floating dosage forms are designed to prolong the residence 
time of the dosage form within the stomach. The dosage form should 
possess sufficient buoyancy to float on the stomach content and 
release the active ingredient at a controlled rate for an extented 
peroid of time. 
The first explicit illustration of floating dosage form was probably 
introduced by Tossounian et al. (1 ). The proposed Hydrodynamically 
Balanced System (HBS™) is an oral dosage form (capsule or tablet) 
mainly formulated with a drug or drugs in combination with a gel-
forming hydrocolloid or mixture of hydrocolloids. When these 
dosage forms are in contact with gastric fluid, it is meant to have a 
bulk density (specific gravity) lower than that of gastric fluids and 
therefore remain 
peroid of time. 
buoyant on stomach contents for an extented 
The inventors claimed that floating dosage forms 
could be used not only to prolong gastrointestinal residence time, but 
also, if required, to obtaine a sustained local action of the latter 
inside of the stomach (1-4 ). 
During the last two decades, several floating drug delivery 
systems and formulations have been developed a1mmg to achieve 
the same intended intragastric buoyance function (5-14). 
The purpose of this article is to review the ongm and 
fundamentals of floating drug delivery systems as they relate to 
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sustained release, to summanze the maJor techniques of 
preparations, to demonstrate examples of few interesting 
applications as well as evaluation methods of these systems. 
2. Development of Floating Dosage Forms 
2.1. Reasons for preparing floating dosage forms 
For at least the last fourty years, sustained release drug delivery 
systems have attracted considerable attention and recognition. In 
these sustained release systems, the oral route of administration has 
received the most attention. This is due to that it is more convenient 
and flexible to design the dosage form for the oral route. The main 
objective rn designing a sustained-release system is to deliver drug 
at a rate necessary to achieve and maintain a consistent and uniform 
drug blood level. In other words, when the dosage form passes 
through the gastrointestinal tract it is necessary for the dosage form 
to provide a constant amount of drug for absorption into the blood 
stream to replace the amount of drug eliminated. 
However, in the case of sustained-release dosage forms, the 
bioavailability of a drug can be affected by the transit of an oral 
dosage form within different regions of the gastrointestinal (GI) tract. 
Some drugs are well absorbed during passage through the GI tract, 
while others are only absorbed from the small intestine. These 
phenomena can be observed m several drugs and particularly for 
vitamins and minerals. This can be due to drug's physicochemical 
properties or favorable sites of absorption, for example, some drugs 
56 
will undergo different degrees of change m solubility by passage 
from the acidic conditions of the stomach to the neutral to alkaline 
conditions of the intestines (15). 
Some vitamins and drugs are primarily absorbed from the upper 
part of the small intestine. A conventional controlled release dosage 
form which may deliver the active ingredient beyond this absorption 
site will not be able to establish an uniform plasma level. Also some 
compounds such as antiacid or nitroso-compound blocking agents are 
intented to act in the stomach, these drugs would loose their most 
beneficial effects if they are passed into the intestine. Also, when a 
drug is administered orally, although there is a certain difference 
depending upon an individual properties and physiological condition 
of the person to be treated, usually it takes one to two hours for 
dosage form to pass away from the stomach to large intestine 
through duodenum and small intestine. Under these conditions, the 
conventional controlled release dosage form of certain types of active 
drug, such as a gastric acid-secretion inhibitor, a gastric acid 
neutralizer and an anti-pepsin inhibitor as well as other therapeutic 
preparations to be absorbed through the wall of the stomach would 
not be appropriate because these drugs are meant to remain and 
provide theitr therapeutic effect in the stomach. In addition, there is 
a drawback that the residual portion of the active ingredient that did 
not release into gastric fluid from the dosage form may subsequently 
release into the intestine and produce unexpected or 
disadvantageous effects. 
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In view of all these reasons and conditions, it is readily apparent 
that very frequently, conventional controlled release dosage forms 
are not suitable for a large number of drugs, vitamins and minerals 
because these dosage forms are not retained in the stomach and/or 
may release the drug beyond the optimum site of absorption result 
m inadequate bioavailability. However, a sustained released 
formulation which can float in the stomach where it acts as a 
reservoir and slowly release the drug over an extended period of 
time will prolong gastric residence time and maximize drug 
absorption in solution when it reaches its absorption site would be 
eminently suited to those drugs mentioned previously. Increased or 
more predictable bioavailability would result from this formulation 
(16). 
The controlled release Hydrodynamically Balanced System (HBS) 
designed by Sheth, Tossounian et al. ( 1) was pioneer of these oral 
floating drug delivery systems. It is a formulation of a drug 
containing gel forming hydrocolloids which remain buoyant on 
stomach content for extended period of time and increase the 
bioavailability. Chlordiazepoxide, diazepam, ferrous salts and several 
vitamins were applied in HBS to reach the desired therapeutic 
response. Sheth and Tossounian claimed that the retentive 
characteristics of HBS floating dosage form are most significant for 
drugs (1) which are insoluble in intestinal fluid, (2) which act locally 
and (3) that exhibit site-specific absorption, however, the HBS dosage 
form also can be used for most drugs where sustained release of the 
active ingredient from the dosage form is desired by the oral route. 
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2.2 Types and principles of floating dosage forms 
Tossounian et al. (16) have demonstrated that the bioefficient 
products utilizing the HBS exhibit improved efficiency and 
bioavailability of some compounds especially for those which are 
absorbed from the upper portion of the small intestine. The HBS 
sustained release formulations comprise a homogeneous mixture of 
one or more drugs with one or a combination of hydrophillic 
hydrocolloids which, in contact with gastric fluid, will form an 
outside gel barrier thus causing it to enlarge somewhat and acquire a 
bulk density (specific gravity) of less than one and therefore remain 
buoyant in the gastric fluid with a resultant prolonged residence 
time in the stomach. The drugs will be gradually and uniformly 
released from the dosage form as the gastric fluid permeates the 
matrix and as the hydrated outer layer slowly dissolves, ultimately, 
after all of the drugs are subatantially released, the gelatinous 
dosage form will disperse. 
In the HBS formulations, the floating capability and release 
characteristics of the dosage form are achieved by the use of specific 
excipients which play an important role in the design of the product. 
It was indicated that the formulation of dosage form must comply 
with three major criteria for HBS products. (a) It is required to 
possess sufficient physical structure to form a cohesive gel layer. (b) 
The system must achieve and maintain an overall specific gravity 
lower than that of gastric fluid (reported as 1.004 to 1.01) result in 
free floating in the gastric fluid of stomach over an extended period 
of time to release all of the drug contents. (c) The dosage form should 
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( dissolve slowly enough to serve as a "reservior" for the drug delivery 
system. 
With respect to the gel-forming barrier, it is also postulated that 
when the HBS dosage form is in contact with gastric fluid, the 
hydrocolloid starts to hydrate by forming a gel layer. This surface gel 
layer then controls the rate of diffusion of gastric fluid in and drug 
out of the dosage form. When the outer surface layer of the dosage 
form goes into solution, the gel barrier structure is maintained by the 
hydration of the immediate adjacent hydrocolloid layer. Meanwhile, 
the drug dissolves in and diffuses out with the diffusing gastric fluid, 
creating a so called "receding boundary" within the gel structure. Tu 
et al. (17) also utilized the principal of HBS to prepare Vit B6 floating 
tablet, the HBS tablets were prepared by wet granulating a mixture 
of HPMC, cetyl alcohol, stearyl alcohol and then compressing into 
tablets. 
Michael et al. (5) utilized a physiologically erodible hollow 
container which has an internal space for housing a drug delivery 
system, this device is comprised of a reservoir for housing the active 
drug Ingredient and it is formed of an esentially imperforate and 
drug release rate-controlling biodegradable material permeable to 
the drug by diffusion. The reservoir is formed of a polymeric 
microporous material having a drug distributed thoroughly and 
whose mi crop ores are a mean for containing a drug release rate 
controlling medium permeable to the passage of drug. This 
reservoir is fixed to a deformable hollow closed member which can 
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inflate on release of the device from its storage container and 
transport container in physiological enviroment and then deflate to 
allow the device to pass from physiological enviroment. The 
invention is designed to provide a floating drug delivery system for 
releasing drug at a controlled rate for a prolonged period of time in 
the stomach. 
Another floating dosage form developed by W.atanabe et al. (6) 
impregnating the active ingredient into a body of empty globular 
shell or a granular lump in small size of a material having high 
buoyancy. They also prepared floating systems by suitably adhering 
a crust of coating containing a desired drug on external and/or 
internal surfaces of a conventional soft or hard capsules having a 
bulk density less than that of gastric fluid in the stomach. In another 
embodiment of their invention, they also plugged a flat tablet 
containing an active drug ingredient into a half piece of a 
compositive capsule and sealed with a binding agent such as 
ethylcellulose dissolved in 1,1, 1- trichloroethane. This half piece of 
capsule was coated with a crust of hydroxypropylmethylcellulose 
phthalate . 
Urquahart and Theeuwes also introduced a floating drug delivery 
system comprising a reservoir containing a plurality of tiny pills (8). 
In this delivery system, the tiny pills have a core of active drug 
ingredient which are coated with a wall formed of a drug-release 
rate controlling fatty acid and wax, these tiny coated pills were then 
6 1 
dispersed throughout a hydrophilic matrix which swells considerably 
in contact with gastric fluid for retaining the device in the stomach. 
A flexible, sheet-like, floating sustained release medicament 
device having a bulk density of less than one was designed by Mitra 
et al. (9), the device is of a multi-layer composite construction 
comprising at least one dry, self-supporting carrier film which is 
formed of one or more water insoluble polymer matrices and drug. 
The sheet or film may have an additional barrier on one or both 
sides. Air spaces are introduced during the manufacturing process 
causing the material to become buoyant. The purpose of the barrier 
film is to control the rate of release of drug that is present m the 
carrier film, another purpose is also to provide buoyancy m the 
stomach. Synthetic polymers are used In the manufacture of the 
sheets and various pharmaceutically acceptable excipients are 
incorporated to obtain desired dissolution and release of the drug. 
This matrix device does not swell in contact with water but maintain 
certain flexibility. The dose is administered by cutting of an desired 
length of the film and folding into a regular capsule, when the 
capsule dissolves in the stomach, the device is left to float on the 
gastric fluid for extended period of time. 
A recent floating sustained release system was prepared by 
Bolton et al. (11 ), the tablets comprise a hydrocolloid gelling agent 
such as agar, a pharmaceutically acceptable inert oil, such as light 
mineral oil, the drug, theophylline and water. The final tablets 
possess a density less than one and therefore will remain buoyant on 
62 
gastric fluid in stomach. Typically, the density of tablet 1s ranged 
from 0.6 to 0.95. In the preparation of this floating tablet, a solution 
of the hydrocolloid gelling agent in warm water and a solution of 
active drug ingredient, theophylline, in the selected oil were 
separately prepared and these two solutions were mixed and cooled 
but not to the point where gelation of the gelling agent takes places, 
the emulsions then were poured into tablet molds and left until the 
gel forms and drying. Although the resulting tablet is not 
compressed, the inventors claimed that the final tablets hardness 
values are comparable to that of most commercially available tablets. 
These tablets have sufficient mechanical stability to stand up to the 
normal stress of production, packaging and despensing. The 
hardness is characterized by a network of multitudinous air holes 
and passages. In this invention, the preferred gelling agent is agar, 
although the inventors claimed other gelling agents may be used. 
These include, for example, agarose, carageenin, konjac gum, alginic 
acid and its salts, cellulose derivatives, carbopol and starch. The 
concentration of gelling agent in the formulation is about 0.5 to 2.0 % 
by weight. It is very suprising to find that such small amount of 
gelling agent are capable of forming such rugged tablets without any 
compression. Beside light mineral oil which has a density of from 
0.828 to 0.880, other hydrocarbon oils or vegetable oils can also be 
employed in the tablet formulation. The inventors concluded that 8 
to 30 % of inert oil is necessary in the initial mixture before gelling. 
Ushimaru ~- also manufactured a floating sustained release 
delivery system consisting a substance which forms gel in water, a 
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( fat/oil which is solid at room temperature and drug (10). These 
substances were simply mixed and filled into a capsule, the capsule 
is heated at the temperature higher than the melting point of the 
fat/oil and then cooled to room temperature, the resulting product 
was then recovered and have a specific gravity of less than 1.0 to be 
able to float on the gastric fluid in the stomach and to undergo 
sustained release of active drug ingredient. 
Another invention relates to a granule remammg m the stomach 
for a prolonged period of time was invented by Ichikawa and his 
coworkers to provide better buoyancy when compared to some 
floating tablets and capsules (12). The granules compnse a core 
containing a active ingredient, foaming layer coated on the core and 
an expansive film coated on the foaming layer. The foaming layer 
was composed of a bicarbonate or a combination of an inner layer of 
a bicarbonate and an outer layer of an organic acid. The expansive 
film was made of a polymer which allow the gastric fluid to 
penetrate into the inside of the granule and then expand like a ballon 
because of the gas evolved within the granule to thereby retain the 
gas within the granule for requred period of time. 
3. Preparation of Floating Dosage Forms 
3.1 Factors affecting floating capability of the dosage forms 
In order to remain buoyant in the stomach for extended period of 
time, it is imperative for HBS dosage forms to maintain an overall 
bulk density lower than that of gastric fluid after they are m contact 
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( with gastric fluid. Ordinarily, the HBS tablets can be manufactured 
on conventional tabletting equipments, however, in accordance with 
the HBS tablets floating principals, HBS tablets can remain buoyant in 
stomach even their initial bulk density is greater than 1 because the 
buoyancy could be obtained from a combination of an increase in the 
bulk volume of the tablet due to the hydration and swelling of the 
hydrocolloid particles on the tablets surface when in contact with 
gastric fluid and the internal voids m the tablet center remaining dry 
due to the barrier formed by the hydrocolloid particles (23 ). 
Therefore, it is essential that the tablet are not compressed so tightly 
that rapid hydration is retarded which result in not obtaining a bulk 
density of less than one after in contact with gastric fluids. 
This critical maximum hardness will vary both with the initial 
density of the formulation and the size of the tablet. Some 
investigations concluded that the effectiveness of the intragastric 
buoyancy of floating systems is dependent on particular 
physiological condition (such as gastric emptying, pH and specific 
gravity of gastric fluid etc.) and dosage forms characteristics (such as 
bulk density of the excipients, hardness of the tablet, size, swelling 
and hydration degree of the final products) (16, 18-26). 
3.2 Technologies of preparing floating dosage form 
The HBS floating dosage forms were initially prepared m a 
capsule form, they were prepared by homogeneous mixing one or 
more drugs with one or more hydrophilic hydrocolloids (27, 28), if 
necessary, fatty material and some inert pharmaceutical excipients at 
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the optimized percentages. The formulations then were passed 
through a Fitzpatrick comminuting machine using different sizes of 
plate or screen at certain speed, the talc or magnesium stearate were 
then added to the formulation as a lubricant and blended for an 
additional time. The blending and milling processes were repeated 
so that the formulation mixture can pass through a certain size mesh 
screen and then the mixture was filled into a optimal size soft or 
gelatine capsules. In the preparation of formulation blends, 
granulation process sometime was required to prepare granules to 
increase floating capability and flowability of the formulation. 
The HBS products were also manufactured in tablet form. Sheth 
.fil..J!l. employed wet granulation process to prepare granules and then 
compressed those granulations into tablet by using certain sizes and 
types of punches and dies on single or rotary press (2, 3). However, 
in the preparation of floating tablets, the hardness of tablet is an 
important parameter to be controlled with respect to the tablet 
buoyancy. In some cases, it was necessary to prepare two different 
granulations separately for the formulation due to the 
physicochemical properties and imcompatabilities of the ingredients 
in the formulation. 
Watanabe et al. utilized spray-pan coating process to apply a coat 
of a high molecular polymer such as a cellulose acetate phthalate and 
an acrylic and methacrylic acids copolymers on the body of capsule 
containing active ingredient and other excipients (6). In another 
embodiment of Watanabe et al. invention, one half of a two piece 
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capsules is plugged with a flat tablet containing an active drug 
ingredient and sealed with a binding agent such as, ethylcellulose 
dissolve in 1, 1, 1 trichloroethane. 
In Michael et al. 's floating drug delivery device, the drug 
containing reservoir which was housed inside the capsules can be 
produced by standard manufacturing procedure, for instance, a drug 
in solid, liquid solution, emulsion form is first mixed with a 
polymeric foaming material which can be monomer, a copolymer or a 
prepolymer in a solid, semi-solid, liquid form (5). The drug is 
distributed thoroughly by ball milling, calendering or stirring and 
then the mixture is shaped into a predetermined shape by molding, 
casting, pressing, extruding or drawing and depending on the 
polymeric material used, cured to yield a drug containing reservoir. 
finally, this reservoir is coated, laminated into a deformable hollow 
member. The deformable member is suitably made of natural or 
synthetic bioerodible materials and it is made of film about 0.4 mils 
to 20 mils thick and the walls of member can be made of a single· 
material, a combination of materials in laminated form or elastomeric 
materials bonded on thin foils. 
Mitra fil..Jll. designed a flexible, sheet-like, sustained release, 
floating multilayers medicament device by overlaying a barrier film 
on at least one surface of the earner film and sealing earner film 
along its periphery in such a way to entrap a plurality of small 
pockets of air between carrier and barrier films (9). The barrier and 
earner films can be prepared by any of the common techniques 
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applied for the preparation of polymeric films. For example, one 
method consists of dissolution of the desired polymer in a suitable 
solvent at ambient temperatures, followed by the addition of other 
ingredients such as platicizer, drug and other additives, to form a 
homogeneous dispersion or high viscosity solution followed by 
coating to a desired thickness. The solvent can be removed by heat 
or evaporation and therefore leaves a self-suppporting film. An 
apparatus is provided for sealing films and entrapping the au 
between carrier and barrier films. 
A floating granules comprise a core of drug, a coated foaming 
layer and another coated expansive film were manufactured by 
Ichikawa et al. using a conventional fluidized bed coating procedure 
followed by drying was used to coat polymer film on the granule 
cores (9). 
In the preparation of Urquhart and Theeuwes floating tablets, the 
powder drug is mixed with sucrose and passed through a 15 to 30 
mesh screen to obtain drug containing cores. Then, a wall-forming 
composition comprising 85 % glycerol monosterrate and 15 % beewax 
in warm carbon tetrachloride is sprayed over cores in a revolving 
coating pan to form a surrounding wall on the cores and produce tiny 
pills. 50 tiny pills are blended with 200 mg of ground reservoir 
forming carboxy-vinyl polymer and compressed into tablet on tablet 
press (8). 
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3.3 Substances used in the preparation of floating dosage 
forms 
In the HBS products, the gel-forming hydrocolloids are the maJor 
component which essentially can be hydrodynamically balanced to 
acquire a bulk density of less than that of gastric fluid when m 
contact with gastric fluid to assure buoyancy, therefore, they play a 
very important role in the floating dosage formulations. 
Hydrocolloids suitable for use in the HBS dosage forms include 
one or more natural, partially or totally synthetic anionic or nomomc 
hydrophillic gums, proteinaceous substances such as, acacia, 
tragacanth gums, locust bean gum, giar gum, karaja gum, agar, pectin, 
carrageen, soluble and insoluble alginates, cellulose derivatives such 
as, methylcellulose, hydroxypropylmethylcellulose 
hydro x ypropy lcell u 1 o se, hydroxy eth y 1 cellulose, sodium 
carboxymethylcellulose, carboxypolymethylene, gelatin, . . casein, zem, 
bentonite, Veegum. Among these substances, 
hydroxypropylmethycellulose 1s a preffered hydrocolloid which was 
mostly used in Sheth et al. inventions (29). Generally, the amount of 
hydrocolloid present in the HBS formulations was between about 20% 
and 75% by weight. 
In HBS dosage form, in order to decrease the hydrophilic property 
of the formulation and also to increase the buoyancy 
pharmaceutically inert, edible, fatty materials having bulk density of 
less than one are often added into formulation, these materials 
include a purified grade of beewax, fatty acids, long chain fatty 
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alcohols such as, cetyl alcohol, stearyl alcohol, myristyl alcohol, 
glycerides such as glyceryl esters of fatty acids or hydrogenated 
aliphatic acid such as glyceryl monostearate, glyceryl distearate, 
glyceryl esters of hydrogenated castor oil and oil such as mineral oil. 
Ushimaru ~- also utilized substances which form hydrated gel 
when poured into water to prepare floating capsules ( 10). These 
substances include cellulose derivatives, dextrans, polysaccharides, 
polypeptides, protein, acrylic acid derivatices, vinyl deravatives. 
more particularly, cellulose derivatives include 
carboxymethylcellulose, carboxyethylcellulose, 
carboxypropylcellulose, carboxymethylcellulose alkali salts, 
carboxypropylcellulose alkali salts, methylcellulose, 
h ydrox ypropy 1eel1u1 o se, h yd rox ypropy 1 methyl cell u Io se, 
hydroxyethy le ell ulose. Starch derivatives include alpha-starch, 
alpha-amylostarch, gelatinized starch, carboxymethyl starch, 
phosphate starch, acid-treated starch, oxidized starch, dialdehyde 
starch, soluble starch, thin boiling starch, dextrin. Dextrans include 
dextran, dextransulfuric acid, carbo xyme.thy ldex tran. 
Polysaccharides include alginic acid, pectic acid, arabic acid, alkali 
salts of arabic acid, chitosan. Gums include arabic gum, tragacanth, 
carrageenan. Polypeptides include polyglutamic acid, polyaspartic 
acid, polylysine, polyalginine. Proteins include gelatin, collagen, 
casein, albumen, g;obulin, gluten. Acrylic acid derivatives include 
polyacrylic acid, polymethacrylic acid, alkali salts of polymethacrylic 
acid, polyacrylic acid-methacrylic acid copolymer. 
include polyvinylpyrrolidone, polyvinyl alcohol. 
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Vinyl derivatives 
They also used 
( fat/oil material which 1s solid at room temperature rn their 
formulations. These fat/oil are higher fatty acids, high fatty acid 
ester derivatives, higher alcohols, higher alcohol ester derivatives, 
and the like. 
In another floating drug delivery system, Michaels et al. have 
used a single material, a combination of materials in laminated form, 
elastomeric materials bonded on thin foils to prepare the deformable 
member walls to be fixed to reservoir for housing the active 
ingredient (5). These materials include silicone, poly(urethanes), 
poly(acrylonitriles), poly( ethylene), poly(propylene), 
poly(acryloni triles), poly( ethylene), poly(propy lene ), poly( vinylidene 
chloride), poly(vinyllidene fluoride), acrylic elastomers, ethylene 
propylene terpolymers. laminates such as poly(ethylene)-poly-
(vinylidene chloride), nylon-poly(vinylidene chloride), etc. The 
reservoir containing active ingredient are made of some nature and 
synthetic polymers which are release rate controlling materials such 
as poly(methylmethacrylate), poly(butylmethacrylate), plasticized 
poly(vinyl chloride), plasticized nylon, etc. and some silicon rubbers 
such as poly(dimethylsiloxanes), ethylene propylene rubber. 
Ichikawa et al. developed granules of drug which can float on the 
gastric fluid rapidly after the administration and maintain the 
buoyant condition for a prolonged period of time ( 12). They 
employed a combination of a bicarbonate and an organic acid to coat 
a foam layer on granular core. Usually sodium bicarbonate is used as 
the bicarbonate while examples of the organic acid are tartaric, 
7 1 
( 
( 
succinic acid and citric acid. It is recommended that the amount of 
the foam layer is 5 to 20% by weight, preferably 10 to 15% by weight 
of the core. They also coated an expansive film on the foam layer to 
retain the gas within the granule for a required period of time. 
Polymers such as polyvinyl acetate, acrylic resrns, shellac, 
hydroxypropylmethyl-cellulose phthalate, cellulose acetate 
phthalate, methylcellulose, ethylcellulose, 
hydroxypropylmethylcellulose are used as expansive film. The 
amount of the expansive film used in the preparation is 5 to 20% by 
weight, preferably 7 to 15% by weight of the core. 
In Bolton et al. 's floating sustained release tablet, hydrocolloid 
gelling agents such as agar, agarose, carageenin, Konjac gum, alginic 
acid and its salts, cellulose derivatives, carbopol and starch. The 
concentration of gelling agent in the final product is about 0.5 to 2% 
by weight (11 ). They also incorporated 8 to 30% therapeutically 
acceptable inert oil include mineral oil, specifically light mineral oil 
which ordinarily has a density of from 0.828 to 0.880, hydrocarbon 
or vegetable oils and waxes. 
Tu fil_fil. also used hydropropylmethylcellulose, cetyl alcohol and 
stearyl alcohol to prepare vitamine B6 floating tablet (17). 
In the floating sustained release capsules prepared by Babu fil_fil., 
hydroxypropylmethylcellulose, methylcellulose, tragacanth, glyceryl 
monostearate and ethylcellulose have been utilized to acquire 
buoyant (14 ). 
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4. Evaluation of Floating Dosage Form 
4.1 In vitro evaluation of floating capability 
Generally, in floating drug delivery system, determination of 
bulk density and measurement of floating duration have been the 
mam parameters used to define the adequacy of the dosage forms 
buoyancy (30). However, some investigations concluded the single 
bulk density determination made before immersion does not enable 
one to forsee the floating force evolution of a solid dosage form, 
while the dry material of which is made progressively reacts or 
interfaces within the fluid to release its drug contents, therefore, the 
density should not completely be considered as a mean of influening 
the gastric residence time of a solid dosage form. To ensure the 
dosage forms floating capabilities verus time, a novel in vitro 
resultant-weight measuring system was recently conceived by 
Timmerman et al. for determining the real floating capabilities 
exhibited by floating dosage forms as a function of time (31-34 ). The 
resultant-weight apparatus enable to monitor the total force F which 
acts vertically on an immersed dosage form. The force F will 
determine the resultant-weight of the dosage form in immersed 
conditfons and can be used to quantify the dosage forms buoyant 
capability. 
The resultant-weight measurement apparatus 1s consisted of a 
linear force transmitter device (FTD) which can maintain the test 
dosage form m a chosen fluid medium and transmitte the reacting 
force F of either upward or downward direction to a connected 
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electromagnetic measunng module of a weighing balance (31, 35). It 
is required to maintain the test dosage form totally submerged into 
the fluid during the determination process, therefore, the lower 
extremity of the FTD is interchangeable for differently designed 
devices such as, mesh-like or needle-like holders, that will be 
choosen for the test dosage form with respect to its morphology and 
characteristics to maintain submerged. The sustained collection as a 
function of time of the continuously measured . resultant-weight 
values can be obtained by recording equipment connected to the 
measuring system. 
The magnitude and direction of force F and the resultant-weight 
correspond to the vectorial sum of the buoyancy (Fbuoy.) and gravity 
(F grav) forces acting on the object; 
F= Fbuoy - Fgrav 
= dr g v - <ls g v 
= (df - <ls) g v 
= ( df - m/v) g v 
Where F represents the total vertical force (resultant-weight of the 
test dosage form); df the fluid density; <ls the dosage form's density; 
g the acceleration of gravity. m the dosage form's mass; and v the 
dosage form's volume. The total force F acting on the immersed test 
sample determines the magnitude and direction of the apparent 
weight of this test sample in the test fluids herein called the 
resultant-weight values signifies that force F is extered vertically 
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upwards and that the test sample is capable of floating , whereas a 
negative resultant-weight indicates that force F applies vertically 
downards and the test sample sinks. Continuous curves of resultant-
weight measurement as a function of time for the different types of 
floating dosage form can be plotted to characterize and quantify the 
floating capability. By using the novel in vitro resultant-weight 
measuring system, Timmermans et al. presented different example 
of floating force kinetics obtained from various polymeric matrix 
floating dosage forms, among these dosage forms several are market 
products and others have been tested m vivo studies on human 
volunteers, the standard test medium was 1200 ml air-free HCl at pH 
1.2 with 0.05% Tween 80 and was thermostatically controlled at 370 
C, meanwhile, some simulated meal media were also used to measure 
floating force kinetics of various floating capsules. They defined the 
floating time of a dosage form as the duration separating time t=O 
(immersion into test fluid) from the time point corresponding to the 
intersection between the positive resultant curve and the zero base-
line. They also quantified the floating capabilities of a dosage form 
by measuring the area under the floating curve, buoyancy AUC. The 
floating curve obtained was also capable of showing that the floating 
capabilities of the dosage forms may undergo various modifications 
upon contact with the fluid. It also tranlates the evolution of the 
hydrodynamical equilibrium and can be used to outline the effects 
upon buoyancy of some of the phenomena happening to the test 
dosage forms. The results obtained from resultant-weight 
measurement indicat that the bulk density of a dosage form is not 
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the most appropriate parameter for ensuring its buoyancy 
capabilities. 
Timmermans et al. concluded that in vitro resultant-weight 
determinations performed as a function of time have enabled 
investigation to reveal important and critical variations within the 
floating force kinetics of dosage forms which had been evaluated to 
be well- floating on the basis of their density characteristic or 
observation of remaining buoyant in a beaker for a certain period of 
time (35). To prevent drawback of unforeseeable floating capability 
variations during in vivo studies, they also strongly suggested 
optimization of dosage form formulation to be realised with respect 
to the significance level, the stability and durability of the floating 
forces produced. 
Tossounian et al. and Bolton et al. determined the bulk density of 
their final floating products to ensure the buoyancy (16, 11 ). 
Tossounian et al. also measured the floating duration of the dosage 
form by observing the products remaining buoyant in a beaker of 
simulated gastric fluid for a certain period of time. Photographs of 
HBS dosage forms remaining buoyant in the beaker were taken at 
different time sequences to asscertain the residence time and the 
floating characteristics. 
Ichikawa et al. evaluated the buoyancy of their floating granules 
by determining the buoyancy ratio (12). Granules were immersed m 
a acetate buffer solution (pH= 4.0) and shaking at a constant rate of 
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( 80 times per minute for a specified period of time, the buoyancy 
ratio therefore was calculated and expressed in the ratio of buoyant 
granules to the total granules sinked in the buffer solution. 
In Usimaru et al.'s slow release floating capsules, a microload 
transformer was utilized to electrically measure the force required 
for shaking dosage form into water, an attachment was connected to 
which capsules are attached for measurement (10). They also 
measured strength or resistance of capsules against shaking and 
floatation at various stages, capsule was put into a 200 ml separatory 
funnel which was filled with 100 ml of water and shaken for 6 hours 
with a KH shaker and then the shape of capsule was photographed 
every one hour and floating duration was also recorded. 
4.2 In vivo evaluation of floating capability 
In order to verify the possible effects of the density of a floating 
dosage form on gastric retention, there are also several in vivo 
determinations were conducted on human volunteers by using either 
noninvasive imaging techniques or drug tracer measurements. 
Timmermans et al., Davis et al. and Kaus et al. determined the 
gastric residence time of various floating dosage forms by the triple 
radionuclide (99mTc, 11 lln and 201 Tl) gamma scintigraphic 
monitoring technique (22,36,37). In their study, three different sizes 
of floating/non-floating pairs were integrated into the scheme of in 
vivo measurement. Anatomical position of the floating dosage forms 
in the gastrointestinal tract was determined as a function of time 
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after precise superimposition of the outlined region of interest on 
each taken sequential image usrng external markers as reference. 
Gastric residence time (GRT) was defined as the time of the image 
preceding the first evidence of gastric emptying of the dosage form. 
Sheth ~., Erni ~. and Watanabe ~. employed X-ray 
positional analysis to confirm the floating and the gastric retention 
characteristics of their floating drug delivery systems (6, 15, 38). In 
the study of HBS capsules, it contain two small barium sulfate for X 
ray analysis. Erni fil.__fil. and Sheth fil.__fil. also utilized external 
scintigraphy to further study the in vivo behavior of the HBS dosage· 
forms, by using this technique, the in vivo behavior of a dosage form 
can be monitored noninvasively minute by minute, the floating 
dosage form was prepared to contain a gamma-emitting radionuclide, 
swallowed by human volunteers and monitored by external 
scintigraphy (16, 38). During the process, between the human 
volunteer and the camera, a collimating plate is placed and only 
those gamma emissions perpendicular to the collimator can penetrate 
to the gamma camera and give position analysis. The computer will 
accumulate the counts impacting on each separate crystal and give a 
quantitative analysis of the radioactivity in any zone covered by the 
total crystal array to show the gastric retention as a function of time 
for the HBS dosage forms. The position and movement of the floating 
dosage form can be visually monitored on television screen. 
Erni ~. studied the floating capability of riboflavin HBS 
capsule, Tiboflavin is known to be well absorbed from the duodenum. 
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( Urinary riboflavin excretion was used as an indirect measurement of 
absorption for HBS capsule and conventional standard capsules. 
They found the rate of absorption with the HBS riboflavin capsules 
was much slower than the one with the standard form and the total 
amount of absorption with the HBS form was by 30% greater than 
the one with the standard form indicating a prolongation of the 
period of absorption. 
Ichikawa et al. utilized roentgenography to monitor the floating 
duration of grnules in the stomach of beagles while Babu et al. used 
the same technique in a human volunteer to determine the location 
and residence time of their HBS capsules in the stomach (12). 
5. Conclusion 
Oral floating drug delivery systems have been shown to increase 
the gastric residence time, efficiency and bioavailability of various 
drugs. The siginificant features and applications provided by a great 
number of patents and some successful development of new 
approaches denote the increasing values and advantages of floating 
delivery systems in the near future. 
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MANUSCRIPT III 
DISSOLUTION, SWELLING AND RELEASE BEHAVIOR OF 
POLYETHYLENE OXIDES: RELEASE MECHANISMS OF FOUR 
DRUGS-PHENYLPROPANOLAMINE HCI, THEOPHYLLINE, 
SOTALOL HCI AND BOVINE SERUM ALBUMIN 
H. R. Chueh, R. W. Korsmeyer* and C. T. Rhodes 
University of Rhode Island, Department of Pharmaceutics, 
Kingston RI 02881 
* Pfizer Central Research, Groton CT 06340 
ABSTRACT 
The swelling and dissolution behavior of different molecular 
weight PEO (polyethylene oxide) polymers in distilled water at 37 Oc 
was investigated. Due to the swelling of PEO matrix discs, 
considerable volume expans10n was observed. Molecular weight is an 
important determinant of PEO dissolution rate, which was inversely 
proportional to the molecular weight of PEO. The results supported 
the hypothesis that dissolution of high molecular weight PEO 1s 
controlled by the inward diffusion of water and outward diffusion of 
polymer through the boundary layer. The influence of the molecular 
size and solubility of four tracer compounds (phenylpropanolamine 
HCl, theophylline, sotalol HCl and bovine serum albumin) and the 
effect of the tracer/PEO ratio on the dissolution rate in SIF ( simulated 
intestinal fluid) were determined. 
85 
INTRODUCTION 
General 
In the formulation of a controlled release dosage form, an often-
used technique is to uniformly disperse a therapeutic substance 
throughout an excipient matrix. Drug molecules may be delivered to 
the environment by various mechanisms including release from 
insoluble matrices, diffusion through insoluble permeable membranes 
or diffusion through swellable hydrophilic polymers., which may be 
erodable or non-erodable or cross-linked. 
In recent years porous hydrophilic polymers have been 
extensively used in controlled and sustained release systems for the 
delivery of various bioactive agents (eg. drugs, insecticides and 
herbicides) (1 ). When a polymer is placed in contact with a 
compatible solvent it generally does not convert directly from the 
solid phase to the solution phase. Often the polymer passes through 
an intermediate swollen gel phase which is evident on the surface of 
the polymer as a soft, tacky mucoid layer (2). In the case of 
crosslinked polymers, there is no release or dissolution of whole 
polymer molecules from the surface, but only mobilization of any 
free segments between cross-links. As a result, a lesser degree of 
swelling occurs and the resulting gel only swells to some equilibrium 
state at which the swelling force and retractive or elastic force are in 
balance. However, if the polymer molecules are not restrained by 
cross-links, and there is no limiting equilibrium state, but rather an 
intermediate condition defined by an "entanglement concentration" 
that progresses eventually to release of polymer molecules from the 
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surface. When the concentration of polymer is below the 
entanglement concentration, the polymer molecules do not interact 
strongly, and the polymer- solvent system behaves as a solution. 
However, when the polymer concentration is above the entanglement 
concentration, the macromolecules are intertwined sufficiently to 
provide some degree of physical integrity and the system behaves as 
a viscoelastic gel. The entanglement concentration is a decreasing 
function of molecular weight. Therefore, a polymer of sufficiently 
high molecular weight will undergo a significant degree of swelling 
before dissolving. The swelling process will exert considerable stress 
on the polymer and crazing may occur at the swelling region. This 
phenomenon can be utilized to release the active agent at a controlled 
rate. 
A number of workers including Lee (3-5), Hopfenberg et al. (6), 
Colombo et al. (7), Korsmeyer and Peppas (8-10) and Hogan ( 11) have 
demonstrated the potential utility of swelling-controlled systems for 
zero order or near-zero order release. Meanwhile, some previous 
contributions including those made by Good (12), Korsmeyer et al. 
(13), Lee (14,15), Peppas et al. (16), and Graham et al. (17,18) 
provided a preliminary understanding of the mechanism of solute 
release from swelling- controlled systems. Peppas and his coworkers 
( 19) recently presented mathematical models to predict the mass of 
drug released and the polymer gel layer thickness as a function of 
time. The recent developments and applications of swelling 
controlled release system have been reviewed by Ranga Rao et al. 
(20). 
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Erosion and Swelling of PEO 
Polyethylene oxide, PEO, ts prepared by the polymerization of 
ethylene oxide, is a water-soluble, glassy, highly crystalline linear 
polymer. The implications for drug delivery of PEO polymers are as 
follows 
A PEO matrix system compnsmg low molecular weight polymer 
should behave as an erodible system, whereas a matrix system 
composed of sufficiently high molecular weight . polymer should 
behave as a swellable system. Swellable and erodible matrix system 
exhibit disparate drug release characteristics. Some of the features of 
drug release from swellable and erodible systems are summarized m 
Table I. 
It should be noted that while the eros10n and swelling release 
mechanisms place different constraints on drug delivery, a system 
containing elements of both erosion and swelling could possibly 
minimize the disadvantages of a system limited to pure erosion 
behavior or pure swelling behavior. Three model situations will be 
examined: pure swelling with no eros10n (cross-linked polymer), 
pure erosion with no swelling(hydrolysis of insoluble polymer to 
produce soluble fragments) , and a hybrid case with inital swelling 
followed by an added erosion component beginning after a lag time( 
after swollen polymer concentration has been diluted below the 
entanglement threshold) In each case, the assumption is that the 
rate of dissolution of drug from any solid drug particle is rapid with 
respect to other processes, so that drug dissolution rate within the 
matrix is not rate limiting. For instance, in one type of system, the 
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polymer matrix is initially glassy and crystalline, so that drug is 
immobilized and cannot diffuse out of the system. Upon entering a 
compatable medium, the polymer would swell and become rubbery 
as it was plasticized by inward diffusion of the medium. Once the 
polymer molecules became mobilized, drug could diffuse through the 
outer swollen polymer layers. Eventually, the outer gel layer would 
reach a certain critical thickness at which point the polymer 
concentration at the outer edge would fall below the entanglement 
threshold( the polymer then behaves as a solution). The swelling rate 
and erosion rate would reach dynamic equilibrium. With a constant 
gel layer thickness and corresponding constant diffusional resistance, 
diffusion of drug through the gel would become release rate limiting. 
Such a swelling controlled system would presumably be less 
dependent on agitation intensity than a different polymer system, 
such as one in which pure surface erosion controlled drug release. 
This agitation-independent characteristic would be desirable since 
agitation intensity is difficult to assess in vivo. 
In an erosion-controlled system, drug molecules would remain 
immobilized within a glassy matrix until the moment at which the 
surrounding matrix eroded and was dispersed into the medium. A 
hybrid system would be one with both swelling and erosion 
characteristics. In such a case, the polymer matrix would swell to 
produce a gel layer, but after reaching a critical thickness, the dilute 
outer edge of the gel layer would begin to erode and disperse into the 
medium. As a result, the gel layer would reach a maximum or critical 
thickness, after which point the gel layer would have a constant 
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thickness. The result would be a constant rate of drug release 
controlled by diffusion through the gel layer. Clarification of the drug 
release mechanisms operating in a given dosage form is useful for 
design and application purposes. 
In general, the behavior of a swellable/erodible delivery system 
is dependent on the relative rates of three processes: (a) the rate of 
water penetration into the polymer matrix (b) the dissolution rate of 
polymer matrix itself, and (c) the rate of drug transport through the 
polymer matrix. A complicating factor is seen for a matrix containing 
a high concentration of a low molecular weight solute. In this case, 
the extent of matrix swelling is initially high due to the high osmotic 
pressure exerted by yet-unreleased solute. Eventually as the solute 
is depleted, the osmotic pressure falls, so that the matrix contracts 
due to dominance of the elastic recovery tendancy of the entangled 
polymer. This also causes a net outward flux of medium as the 
matrix contracts, and dissolved solute or drug is carried outward at 
an enhanced rate greater than that due to diffusion alone. Any one or 
a combination of these processes may control the rate of drug 
delivery from a system. In the present investigation, the processes of 
swelling and erosion were studied for different molecular weight 
types of a model polymer, poly(ethylene oxide) (PEO). 
EXPERIMENTAL 
Materials 
The six grades of PEO used in this study are shown in Table II. The 
water soluble tracers used in these studies are listed in Table III. 
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Preparation of Polymer Matrix Tablets 
The polymers were sieved to exclude particles larger than 177 um. 
samples were prepared in the form of discs by direct compression of 
370 mg of pure PEO using flat-faced , 5/8 inch (1.59 cm) punches 
and die. A Carver press was employed at a compression force of 
5000 lbs with a dwell time of 10 seconds. The resulting compaction 
pressure was 16,246 psi on the upper tablet surface. The 
manufacture of tablets resulted m correspondingly thicknesses of 
0.062 inch. The size and shape (thin discs) of the tablets were 
selected to simplify interpretation of the swelling . and dissolution 
data, rather than to represent a tablet design suitable for human use. 
Swelling and Erosion Experiments with PEO Matrix Tablets 
For each PEO type, three 370 mg tablets were prepared. For 
dissolution studies, a sample tablet was suspended beneath the 
surface of the dissolution medium in a USP dissolution flask by means 
of a 21 gauge synnge needle piercing through the center and normal 
to the planar surface of the sample tablet. The needle-mounted 
tablets were fastened to disposable syringes, which provided 
convenient handles for manipulating the samples. The tablet sample 
was positioned so that the tablet was 1 cm from the paddle shaft and 
1 cm above the paddle blade. The flasks were filled with 900 ml of 
dissolution medium. Each flask was fitted with a USP paddle spaced 
at 2 cm above the flask bottoms and rotating at 110 rpm. The 
temperature was maintained at 37oc +/- 0.5 by a heater-circulator. 
The tared tablet holder with attached tablet sample was removed, 
excess liquid was allowed to drain , and then the assembly was 
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weighed at specified intervals until the tablet became distorted. (no 
longer disc shaped). Samples (2.5 ml) of the dissolution medium were 
withdrawn at specified time intervals for analysis of the mass of PEO 
dissolved from a sample tablet by determination of the PEO 
concentration using Differential Refractometry. Standard curves were 
prepared for each type of PEO m which the refractive index ratios ( 
solution/distilled water) were plotted versus the polymer 
concentration. The standard curves were linear over the sample 
concentration range so that dilution was not required. The rapid rate 
of dissolution of the PEO 3.5K precluded obtaining weight 
measurements. 
Diffusion/Dissolution Studies of Drug-Containing PEO Matrix 
Tablets 
Tablets were prepared by direct compression of 500 mg of well-
mixed powder blend composed of drug and the selected type of PEO. 
Mixing of each 10 gram blend was carried out for five minutes m a 
small bottle which was filled to 10 percent of capacity mounted in a 
twin arm blender. Tablets were compacted using 7 /16 inch bevel-
edged punches in a Carver press at a compress10n force 5000 lbs for 
10 seconds. The tablets hardness was greater than 20 Kgf, and tablet 
thickness was about 4mm. 
For tablets containing a mixture of drug and PEO particles, 
dissolution studies were performed by using the USP paddle method 
at 50 rpm in simulated intestinal fluid USP (SIF) at pH 7 .5, at 37oc. 
The concentration for theophylline, sotalol HCl and PPA.HCl were 
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determined by monitoring the absorbance at 272 nm, 228nm and 214 
nm, respectively, in a spectrophotometer. Standard curves of 
prepared theophylline and PPA.HCl solutions showed that plots of the 
absorbance at 272 nm, 228 nm and at 214 nm versus theophylline, 
sotalol HCl and PPA.HCl concentration, respectively, were linear. For 
dissolution studies utilizing BSA, dissolution medium samples were 
diluted with blank dissolution medium as required to produce tracer 
concentrations within the standard curve range. The . concentration of 
BSA was measured by the Bradford protein assay method (21). 
RESULTS & DISCUSSION 
Swelling Behavior of PEO Matrix Tablets 
The swelling behavior of polyethylene oxide samples of different 
molecular weights is demonstrated in Figure 1 and 2. The swelling 
behavior is presented in terms of the water uptake. The tablet water 
uptake was calculated by subtracting the dissolved polymer weight 
from the initial dry polymer weight to obtain the remaining polymer 
weight (dry basis). Next, the remaining dry polymer weight was 
subtracted from the gross weight of the wet tablet sample. The PEO 
3.5K tablets 1ssolve smoothly and rapidly, with no visible gel layer 
being formed, hence its swelling profile is not shown. The weight 
curves of PEO lOOK and 200K show three distinct phases. Initially, 
the samples imbibed water rapidly. Next, an intermediate gel state 
was observed, and finally dissolution (erosion) of tablet matrix 
occured. 
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In the cases of PEO 1 M, PEO 4M and PEO 5M, the tablet underwent 
considerable swelling before dissolution. The swelling of these high 
molecular weight PEO tablets appears to be diffusion rate controlled. 
As shown in Figures 3, 4 and 5, the plots of tablet weight vs. the 
square root of time yield the characteristic straight line associated 
with a rate-limiting gel layer of increasing thickness. Similar results 
were reported by Parsonage ~ (22) for different polymers. 
The dynamic swelling process of a representative PEO sample is 
illustrated in the series of photographs shown m Figure 6 to Figure 9, 
in which the PEO tablet has been swollen m water. The initially 
glassy polymer tablet is gradually converted into a rubbery, 
plasticized state by diffusional influx of water, which acts as a 
plasticizer for these polymers. The photographs show that a region of 
high stress (the bright region as seen in the photograph due to the 
photoplastic effect) develops when the outer portions of the polymer 
begin to swell. This stressed area moves inward as swelling develops 
until stress relaxation occurs. This stress rearrangement is 
associated with plasticization of the center of the tablet. 
Effect of Molecular Weight on the Release of PEO 
The dissolution profiles of different molecular weight PEO are 
shown in Figure 10 and 11. As can be seen, the PEO samples of 
different nominal weights have different dissolution properties, the 
dissolution rate decreasing as the molecular weight is increased. The 
dissolution of PEO is clearly controlled by the molecular weight. The 
precise nature of this relationship is a function of the type and time 
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dependence of the rate-controlling step. If dissolution is controlled 
by diffusion of a polymer molecule across a fluid boundary layer, 
then the rate should be proportional to the diffusion coefficient in 
solution which according to the Sutherland- Einstein equation, 
depends on the reciprocal of the diameter of the molecule. In turn, 
the diameter of a polymer molecule in solution is proportional to 
molecular weight. 
D = RT I 6 11 n r N 
where: D is diffusivity, n is solution viscosity, r is molecular radius 
and N is Avagadro's number. Thus, this release mechanism( 
diffusion across a boundary layer) yields a dissolution rate that is 
proportional to molecular weight. 
If instead, dissolution is controlled by the time it takes a polymer 
chain to disentangle itself from a concentrated gel, then the rate 
should be proportional to a higher power of molecular weight. 
Ueberreiter (23) proposed an empirical relationship between 
molecular weight and dissolution rate: 
G = K x Mw-A 
where G is the dissolution rate, Mw is the molecular weight, K and A 
are constants. 
This is similar to the Mark- Houwink equation, 
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[n] =KMa 
where: [ n ] is the intrinsic viscosity of a polymer dispersion, M is 
the polymer molecular weight, K and a are characteristic for a 
particular polymer-solvent system. At the outer margin of gelled 
polymer, the polymer concentration falls below the entanglement 
concentration and causes the polymer to behave as a fluid. Higher 
molecular weight would produce a higher intrinsic viscosity. A fluid 
dispersion with higher intrinsic viscosity would be expected to show 
slower dissolution. 
Taking the log of both sides of the Ueberreiter equation yields 
the equation of a straight line: 
log (G) = log K - A log (Mw) 
The log (dissolution rate) vs. Log (Mw) of PEO is presented in 
Figure 12. The slope 1s -0.65 (S = 0.05). This value seems more 
supportive of the boundary layer mechanism than the 
disentanglement mechanism. 
On the dissolution study of PEO 3.5K, the tablets dissolve directly, 
with no observable intermediate gel state, one would expect that a 
drug-containing matrix of this material would release the drug at a 
rate equal to the polymer dissolution rate. As shown in Figure 10, 
the dissolution of the PEO lOOK is constant until most of tablet (75% 
or so) is dissolved. The dissolution rate does not vary with tablet 
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thickness. This is due to a nearly constant tablet surface area during 
the dissolution study. For the thickest ( 0.62 inch ) of these tablets, 
the initial sidewall surface area ( As= 2 11 r h) is only 20 % of the 
initial combined obverse and reverse tablet areas ( Aor = 2 11 r 2 ). 
The weight curves of PEO 1 OOK (Fig. 1) show that tablet picks up 
water relatively rapidly at first, but then the rates of dissolution and 
water penetration come into balance. This kind of dissolution 
behavior is desirable for controlled release. The PEO lOOK 
dissolution appears to proceed by a pseudo-steady-state process in 
which an outer gel layer is continuously formed as water penetrates 
the tablet and is simultaneously eroding at the outer boundary. 
Since both water penetration and dissolution are proceeding at the 
same rate, it does not matter which process controls release of the 
drug. A drug which can diffuse through the gel layer has a barrier of 
constant thickness to traverse and remaining drug is released from 
the outer boundary when the polymer dissolves. 
The dissolution results of PEO 4M and PEO 5M (Figurel 1) 
indicated that they are more useful for controlled release on a longer 
time scale than the lower molecular weight polymer. However, since 
the matrix swells considerably before dissolving, different drugs 
should be released at different rates, depending on whether they 
diffuse easily through the gel or only released by dissolution of the 
tablet polymer matrix. The drug solubility and molecular size of a 
drug limit release: Very low drug solubility may produce matrix 
dissolution rate control, or controlled by a rate limiting step of 
dissolution of drug molecules from the surface of individual drug 
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( particles inside the polymer matrix. On the other hand, high drug 
solubility may result in drug diffusion rate limited rate control. 
Influence of the Molecular size and Water-Solubility of the 
Tracer on PEO Matrix Dissolution 
The effect of the water solubility and molecular size of tracers on 
the magnitude of the release rates and type of diffusional release 
was determined using four solutes, PPA.HCl, anhydr.ous theophylline, 
sotalol HCl and BSA release from PEO matrix systems. 
The solute release data of the early portion of the release curve 
(Mt/Moo <0.6) from PEO matrix system were analyzed by using Eqn. 
1, where Mt/Moo represents the fraction of drug released at time t, 
K is the kinetic constant characteristic of the drug/polymer system, t 
IS the release time and n is an exponent characterizing the 
mechanism of release of the drugs. The corresponding release rate 
per unit area of exposure can be obtained from Equation 2, where A 
is the surface area of the sample, Cd Is the drug loading 
concentration. 
Mt/Moo =Ktn (Eqn. 1) 
dMtl Adt = n Cd K t n - 1 (Eqn. 2) 
Table IV summanzes the range of values of the diffusional exponent 
n, and the corresponding release mechanism. 
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The values of K, n and correlation coefficient (r2) obtained from 
various formulation of PEO lOOK and PEO 5M are given in Table V. 
As shown in Table V, in the case of PEO 1 OOK the n values of 
PPA.HCl, sotalol HCl and BSA are in the range of 0.45-0.89 indicating 
that drug was released by non-Fickian behavior and the n value of 
theophylline are relatively high indicating Super Case II transport. 
In PEO 5M systems, the n value of PPA.HCl, theophylline, sotalol HCl 
and BSA are all in the range of 0.45-0.89 indicating that the drug 
was released by Anomalous transport. The n values also indicated 
that the release of these three solutes were at least partially 
controlled by viscoelastic relaxation of the matrix during solvent 
penetration. 
Release profiles of three solutes from the matrices containing PEO 
lOOK or PEO 5M (50% solute/50% PEO) are shown in Figure 13 and 
Figure 14, respectively. As shown in Figure 10, drug-containing PEO 
lOOK tablets exhibited a linear release profile for approximately two 
hours. Although the three solutes were released at different rates, 
these rates did not vary widely. The diffusion coefficient as 
predicted from the tracer molecular weights are quite disparate, 
leading to the conclusion that the observed similarity in tracer 
release rates is probably due to matrix erosion-controlled drug 
release. This would mean that the gel layer thickness is very small 
so that most of the mass of drug particles is released into the 
external medium before drug is dissolved. This is probably due to 
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the dissolution rate was essentially controlled by the erosion of PEO 
lOOK matrix. 
Figure 14 shows that the release of PPA.HCl (smaller molecular 
size, high diffusivity) from PEO SM had the faster release rate while 
theophylline (smaller molecular size, lower solubility) exhibited an 
intermediate release rate, the release rate of theophylline from PEO 
SM was nearly constant (zero order) in the first 20 hours. The 
release of BSA (larger molecular size) from PEO SM appeared to be 
more controlled by its low diffusivity in the gel layer formed as the 
tablet swelled. 
As shown in Table V, the kinetic constant for release, K, which 
incorporated the overall solute diffusion coefficient and geometric 
characteristic of the system correlated inversely with the solute 
molecular weight. K also increased with increasing total solubility of 
the matrix system. The K values of all three solutes in a PEO lOOK 
matrix are greater than those in a PEO SM matrix. 
Effect of The Tracer/PEO Ratio on The Dissolution Rate 
The effect of relative amount of tracer in the PEO formulation on 
the dissolution rate is shown in Figure 1 S and Figure 16. In the case 
of PEO IOOK (Figure IS), tablets prepared with 4 wt% BSA and 96 
wt% PEO lOOK exhibited faster release than the SO wt% BSA/SO wt% 
PEO lOOK, this is due to the dissolution of PEO lOOK is faster than the 
dissolution of BSA. The dissolution rate of the system is essentially 
controlled by erosion of PEO lOOK matrix. However, as shown in 
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Figure 16, tablets composed of 50 wt% BSA and 50 wt% PEO 5M had 
faster release rate than the 4 wt% BSA/96 wt% PEO 5M. This is 
attributed to the fact that PEO 5M matrix swells more extensively 
and the release of BSA is mostly controlled by its low diffusivity in 
the gel layer. As the relative amount of PEO 5M in the system was 
increased, the resistance of the gel layer to diffusion of drug was also 
increased. 
CONCLUSIONS 
These findings conclude that molecular weight is an important 
determinant of PEO dissolution rate, which was inversely 
proportional to the molecular weight of PEO and the release of drug 
from PEO matrix system follow some anomalous behavior where both 
diffusion and mechanical relaxation affect the whole process. In the 
case of theophylline, the release rates are nearly zero order. If a 
mixture of different molecular weight PEO is chosen carefully, it is 
quite possible to balance the reduction in resistance to diffusion of 
the drug, leading to drug/PEO systems which exhibit constant release 
rate. 
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( TABLE I. Drug release characteristics of swellable and erodible 
systems 
Swelling Controlled Systems 
* release can be zero order 
* drug must diffuse through 
gel (drug solubility and high 
molecular weight may limit 
release) 
* matrix swelling is largely 
independent of agitation 
intensity of medium 
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Erosion Controlled systems 
* release can be zero order 
* largely independent of 
drug( it can deliver insoluble 
and high molecular weight 
drugs) 
* matrix erosion is highly 
dependent on agitation 
intensity of medium 
( TABLE II. Various grades of PEO used m diffusion and dissolution 
studies. 
Designation Nominal Molecular Weight Source 
3.5 K 3,350 Sigma 
100 K 100,000 Union Carbide 
200 K 200,000 Union Carbide 
lM 1,000,000 Union Carbide 
4M 4,000,000 Union Carbide 
5M 5,000,000 Polysciences 
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TABLE III. Different tracers used m the dissolution studies. 
Tracer Water solubility Molecular Weight Source 
Theophylline 8.3 mg/l ml 180.17 Sigma 
PPA. HCl 909 mg/I ml 187.67 Sigma 
Sotalol HCl 200 mg/I ml 308.8 Bristol-Myer Squibb 
BSA 69,000 
PPA. HCl = Phenylpropanolamine Hydrochloride USP 
BSA = Bovine Serum Albumin ( Cohn Fraction V ) 
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TABLE IV. Diffusional exponent and mechanism of diffusional 
release from cylindrical swellable controlled release 
matrix system 
Diffusional exponent (n) 
< 0.45 
0.45 < n < 0.89 
0.89 
n > 0.89 
Drug release mechnism 
Fickian diffusion 
Anomalous (non-Fickian) transport 
Case II transport 
Super Case II transport 
when the value of n = 0.89 means that the drug release is 
independent of time, the release is characterized as zero-order 
release. 
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( TABLE V. Vaules of Kinetic Constant (K), Release Exponent (n) and Correlation Coefficient (r2) Following Linear Regression of 
Dissolution data Analyzed by Equation 1. 
System Kinetic Constant Release Exponent Correlation 
K (h-n) (n) coefficient 
(r2) 
PPA.HCl/PEO lOOK 0.46 0.68 0.992 
Theophylline/PEO IOOK 0.42 1.10 0.999 
Sotalol HCl/PEO 1 OOK 0.45 0.76 0.996 
BSA/PEO lOOK 0.37 0.78 0.998 
PP A.HCl/PEO 5M 0.24 0.51 0.992 
Theophylline/PEO 5M 0.05 0.83 0.999 
Sotalol HCl 0.05 0.75 0.997 
BSA/PEO 5M 0.04 0.66 0.996 
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Figure 6 - Dynamic swelling process of a representative PEO 5M 
tablet in water ( time = 0 hour) 
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Figure 7 - Dynamic swelling process of a representative PEO 5M 
tablet in water (after 2 hours) 
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Figure 8 - Dynamic swelling process of a representative PEO 5M 
tablet in water (after 6 hours) 
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Figure 9 - Dynamic swelling process of a representative PEO 5M 
tablet in water (after 8 hours) 
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MANUSCRIPT IV 
OPTIMIZATION OF SOTALOL FLOATING AND BIOADHESIVE 
EXTENDED RELEASE TABLET FORMULATIONS 
ABSTRACT 
A novel extended release sotalol HCl tablet formulation which 
possesses an unique combination of floatation and bioadhesion for 
prolonged residence in the stomach was developed. Tablets were 
produced by direct compression process. A two-factor factorial, 
central, composite Box-Wilson experimental design was employed to 
develop and optimize the tablet formulation containing 240 mg 
sotalol HCl and some other polymeric components. The ratio of two 
major bioadhesive agents, sodium carboxymethylcellulose (NaCMC) to 
hydroxypropylmethylcellulose (HPMC), and the ratio of two direct 
compressible diluents, ethylcellulose (EC) to crosspovidone, were 
used as formulation variables (independent variables) for optimizing 
some tablets response parameters, such as dissolution characteristic, 
bioadhesive capability, tablet density and required compression 
force for producing 6 Kg hardness tablets. The data were also 
analyzed by means of quadratic response surface model. Response 
surfaces were generated as a function of formulation variables. An 
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optimum direct compression, bioadhesive and floating tablet 
formulation of sotalol HCl was achieved by considering the 
dissolution characteristic as primary objective and using required 
compression force, bioadhesive capability as constraints within the 
experimental region. The surface model was validated for accurate 
prediction of response characteristics. 
INTRODUCTION 
For the last fourty years or so, oral sustained-release drug 
delivery have attracted considerable attention and recognition (1). 
However, in the cases of certain classes of active ingredients which 
are not suited to normal absorption during passage through the 
gastrointestinal tract (GIT), the conventional oral sustained-release 
dosage forms can be disadvantageous due to their physicochemical 
properties or favorable absorption site (2). Some drugs will undergo 
different degrees of change in solubility by passage from the acidic 
condition of the stomach to the neutral or alkaline condition of the 
intestine. In view of all these reasons and conditions, it is readily 
apparent that very frequently the bioavailability of these drugs in 
conventional sustained release dosage form can be affected by the 
transit of the dosage form within different regions of the GIT. 
In recent years, many attempts have been made to provide 
therapeutic dosage form .which will provide longer transit time and 
more efficient absorption for specific drugs which have a window 
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effect of absorption or stability problem. The floating dosage form 
was designed to possess sufficient buoyancy to float on the top of 
stomach content and prolong the stomach residence time of the 
dosage form (3-8). Meanwhile, significant interest also has been 
shown in the development of oral bioadhesive systems to adhere the 
oral dosage form to mucosa wall of stomach or intestine to increase 
the residence of the drug in the GI tract (9-12). 
The floating and bioadhesive drug delivery systems are meant to 
provide the following advantages (1) increased and more effective 
absorption for drugs which have specific absorption sites (2) 
increased contact time for local activity in the stomach where such is 
required and (3) the ability to limit the number of dosages. 
The floating dosage form is meant to remain buoyant on the 
gastric fluid when the stomach is full after a meal, however, as the 
stomach empties and the tablet is at the end of the stomach the 
buoyancy of the dosage form might be impeded (13). It will become 
increasingly possible that the dosage form will pass through the 
pylorus into the small intestine. Thus, the buoyant ability of a 
floating drug delivery system in the stomach could be limited to only 
three or four hours. In bioadhesive drug delivery system, it is quite 
likely that the system becomes dislodged from the stomach mucosa 
wall when the stomach is full and semi-liquid contents are churning 
around under the influence of peristaltic movement. Also, most of 
currently available oral floating and bioadhesive systems are made 
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by wet granulation tabletting process and some other tedious and 
costly procedures. 
In light of the above reasons and conditions, the objective of this 
work was to develop a novel sustained-release tablet made by direct 
compression process. The tablet possesses an unique combination to 
prolong the stomach residence time of sotalol HCl, a beta-blocker, 
which has high aqueous solubility and its absorption from GI tract is 
limited to the upper part of the small intestine. 
In this present study, a computer optimization process utilizing a 
statistical Box-Wilson design experimental design (14, 15) was 
employed to develop bioadhesive and floating tablet formulations 
and determine the effects of formulation variables on the response 
properties of tablets. Finally, an optimum tablet formulation was 
selected using the technique of response surface methodology. 
EXPERIMENTAL 
Experimental Design 
The two formulation variables and their ranges selected for 
optimization study were summarized in Table I, Xl represents the 
ratio of NaCMC(mg) to HPMC(mg) and the second variable, X2 
represents the ratio of EC(mg) to polyplasdone XL(mg). All other 
formulation and processrng variables were remained constant 
throughout the study. 
129 
A total of 13 experiments required in a two factor factorial, 
central, composite Box-Wilson experimental design was listed in 
Table II. This experimental design is based on factorial design with 
additional points added to estimate curvature of the response 
surface. As shown in Table II, the first sixteen experiments 
represent a half-factorial design for two factors at two levels 
represented by + 1 and -1, analogous to the high and low values in 
any two level factorial design. For the remaining experiments, three 
additional levels, +1.414, 0, -1.414 were selected. The zero level 
represents a center point midway between the + 1 and -1, the levels 
noted as +1.414 and -1.414 represent extreme values for each factor 
and the experimental levels were calculated by adding or subtracting 
one-half experimental unit to or from the experimental levels 
corresponding to + 1 or -1 m the experimental design. The design 
also includes five replicate of center point allowing a lack-of-fit test 
for the mathematical model. Standard designs with fewer trials 
would have resulted in confounding among model terms and 
increased the risk of inaccurate conclusion. 
Table III shows the translation of the experimental levels in the 
statistical design into experimental values. The response parameters 
measured on the resulting tablets were summarized in Table IV. The 
objective was to search the levels of the two independent variables 
that would produce tablets with the desired response parameters. 
These parameters are Y 1, dissolution characteristic (diffusional 
exponent, n); Y2, the detachment force required to separate tablet 
from membrane; Y3, the required shear force; Y 4, the required 
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compress10n force for producing 6 kg hardness tablets; Y5, tablet 
density. 
Preparation of Bioadhesive and Floating Tablets 
Materials--- Sotalol hydrochloride (Bristol Myers-Squibb lot NOC07) 
was used as active ingredient in the formulation. The following 
materials were also used: sodium carboxymethylcellulose (NaCMC 
7HF, Aqualon Co., Lot 67798), hydroxypropylmethylcellulose (HPMC, 
Methocel K15M Premium CR Grade, Dow Co., Lot MM89011881K), 
ethylcellulose, (EC, Ethocel Premium V-10, Dow Co., Lot 6161187), 
crosspovidone NF (Polyplasdone XL, GAF Chem. Co., Lot S01029), 
calcium carbonate (Amend Chem Co., Lot 837399805) and 
magnesium stearate (Fisher Scientific Co., Lot 742748). Tablets were 
prepared with the following formulations based on the experimental 
design described above. 
Sotalol HCl 240 mg 
NaCMC 11 to 209 mg 
HPMC 11 to 209 mg 
ff: 17.6 to 102.4 mg 
Polyplasdone XL 17.6 to 102.4 mg 
Calcium carbonate 80 mg 
Magnesium stearate 2 mg 
In the tablet formulation, NaCMC and HPMC were used as 
bioadhesive agents. When the tablet is in contact with gastric fluid, a 
combination of NaCMC and HPMC will also possess sufficient 
structure to form a gel layer and achieve an overall specific gravity 
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lower than that of gastric fluid therefore remain buoyant m the 
gastric fluid. Meanwhile, calcium carbonate was used in the 
formulation to generate carbon dioxide, these carbon dioxide bubbles 
will become entrapped by the hydrated outer gel layer to enhance 
the buoyance of the tablet. EC and polyplasdone XL were used as 
direct compressible tablet matrices in the tablet formulation. 
Mix in i:--- All powders except Mg stearate were sieved through sieve 
of mesh size 20. The components of the formulation were mixed for 
15 minutes in a WAB type T2C turbula mixer. 
Lubrication--- Mg stearate (40 mesh sieved) was added into powder 
blend as a lubricant and mixed for an additional of 3 minutes before 
compaction process. 
Compaction--- Tablets were prepared by direct compression on an 
instrumented Stoke B-2 rotary press at 30 rpm using 3/8" flat face 
punches and dies adjusted to obtain 6 kg hardness tablets. The 
required compression force was measured by the piezoelectric force 
transducer located in the eyebolt. The analog data from the 
piezoelectric force transducer were converted to the digital form by 
the analog to the digital converter. The digital output was then 
collected and analyzed on a personal computer. The tablet 
formulations were compressed m a random order. 
Tablet Evaluation 
In Vitro Dissolution--- Dissolution studies were conducted usmg the 
USP basket method. Six tablets were tested for each batch. The 
dissolution medium was 900 ml of 0.1 N HCl solution (pH 1.2) 
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equilibrated at 37 °C and stirred at 70 rpm. The samples (3 ml) were 
withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 20 and 24 hours, respectively. The 
dissolution medium volume was kept constant by adding the same 
volume of fresh dissolution medium kept at the temperature of 37 °C. 
The dissolution samples were diluted and the concentration were 
determined on a Diode Array Spectrophotometer at the wavelength 
of 228 nm corresponding to the maximum absorbance of sotalol HCI. 
Floatin~ Capability--- The lag time required for the tablet to start 
floating on the top of basket in the dissolution study was measured. 
The duration of floatation under the rotating condition of the 
dissolution study was also determined for all formulations. 
Measurement of Bioadhesiveness 
Figure 1 shows the diagram of the custom-designed apparatus to 
be equipped with Instron Tensile Tester (lnstron, model 1122) for 
bioadhesion measurement. The system consists of a small 
polyacrylic cylinder fastened to the side wall of a polyacrylic cubic 
vessel to hold the membrane by means of an 0-ring. A retangular 
aluminum pieces with a hole in the middle was used as a support to 
hold the tablet fixed over the surface of the biological tissue. The 
vessel was put on the lower plate of the lnstron Tensile Tester, while 
the aluminum support was connected to the vertical rod and fixed to 
the upper clamp of the tensile tester. 
In a typical sliding adhesion test, after placing the tablet in the 
hole of the aluminum pieces, the stomach mucosa and tablet were 
brought together just to touch each other. The tablet and mucosa 
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surfaces were held parallel. The vessel was filled with constant 
volume of distilled water ( 1000 ml) at 22 °C. After 30 minutes (pre-
s welling time), the force was measured and recorded as a function of 
time until the tablet had crossed the mucosa surface. Additionally, 
as can be seen from Figure 1, another polyacrylic cylinder is fixed to 
the bottom of the vessel to hold a mucosa horizontally by means of 
an 0-ring for the determination of direct detachment force . 
In the detachment force measurement, the tablet was stuck on to 
retangular aluminum support with a cyanoacrylate glue, the tablet 
support was fixed to the upper clamp of the tensile tester and 
lowered to maintain in a similar fashion that tablet and rabbit 
stomach mucosa surfaces were rigorously parallel. The cubic vessel 
was filled with constant volume (1000 ml) of pH 2 buffered solution 
at 22 °C. After 30 minutes, the crosspiece was raised at constant 
speed (20 mm/min.) The detachment force was measured and 
recorded as a function of displacement, up to the total separation of 
the tablet surface and tissue. The adhesion work was determined by 
calculating the area under the curve necessary for detachment. 
The biological tissue used m bioadhesion study was rabbit 
stomach mucosa, it was maintained m normal saline solution or used 
immmediately after the sacrifice of the animals. The stomach 
mucosa samples were immersed in normal saline solution and kept 
in the refrigerator at 5 °C before use. 
Analysis of Data 
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All the statistical and regress10n analysis procedures on the 
response parameters were performed using the X-STAT software 
package. Statistical Analysis was carried out which includes the 
calculation of mean values for each of the four response parameters 
in each of 13 experiments. 
The sets of data obtaining from the statistical analysis were then 
subjected to computerized regression analysis to determine the fit to 
a second-order model. These regression models include an intercept 
and main effect terms of each independent variable, two-way 
interaction terms and second order effect terms as shown in Table V. 
RESULTS AND DISCUSSION 
The dissolution profiles for the tablets are shown m Figure 2 to 
Figure 5. The sotalol HCI release data of the early portion of the 
release curve (Mt/Moo < 0.6) from floating and bioadhesive tablet 
were analyzed by using Equation 1, where Mt/Moo represents the 
fraction of drug released at time t, K is the kinetic constant 
characteristic of the drug/polymer system, t is the release time and n 
is an exponent characterizing the mechanism of release of the drugs 
(16). 
Mt/Moo =Kt n (Eqn. 1) 
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Table VI summarizes the range of values of the diffusional 
exponent n, and the corresponding release mechanism. 
The response properties of tablets obtained from all 13 
formulations in the experimental design were summarized in Table 
VII. The n values of sotalol dissolution are in the range of 0.36 to 
0.60. The lag time of tablet floatation ranged from 5 seconds to 12 
minutes. All tablet formulations exhibited floatation capability and 
maintained buoyant for more than 24 hours in dissolution medium 
under rotating condition. The required detachment force of tablets 
in bioadhesion study ranged from 1.0 to 2.11 Newton(N), the shear 
force ranged from 0.64 to 1.67 N. The required compression force 
are in the range of 8.42 to 21.68 kilonewton(KN). For each response 
parameter, variations were observed among formulations. 
Each response parameter was fit to the second-order polynomial 
model and the regression coefficient for each term m the regression 
model were shown in Table VIII to XII. As can be seen, most of 
these standard error values are less than 50% of the absolute values 
of their regression coefficients indicating the adequacy of the model. 
Also, the high values of confidence level indicate these variable 
terms have standard significant effects on the response parameter. 
Although, there are few terms which do not contribute significantly 
at 90% confidence level to the model, however, these terms, as a 
group, do affect the shape of the contour plot. 
As shown in Table XIII, the high R2 values of each response 
parameter equation indicate the good fit and adequacy of these 
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models. It also implies that the regression equation explains large 
portion of variation of response parameter about its mean. For each 
response parameter, the multiple correlation coefficient was greater 
than 0.91 indicating there are at least more than 91 % of the total 
variations observed in the response parameter could be explained as 
being caused by the independent variables rn the way described by 
the equation as shown in Table VIII to XII. An F test for the 
regression equation was performed and the calculated F value was 
significant at the 99% level for all response parameters revealing 
that these model terms are important for explaining variability. 
Also, the predicted minimum and maximum values for each response 
parameter show good agreement with the experimental results 
obtained from 13 batches shown in Table VII. 
The general quadratic surface model was applied to generate 
contour plots for each of response parameters. Figure 6 shows the 
effect of two formulation variables, NaCMC/HPMC and 
EC/polyplasdone XL, on tablet dissolution characteristic (diffusional 
exponent value, n). It indicates that tablets made with 105 mg 
NaCMC, 115 mg HPMC, 90 mg EC and 30 mg polyplasdone XL 
obtained the highest n value from dissolution profile which indicates 
sotalol HCl was released by non-Fickian behavior, a near zero-order 
release, and the release was partially controlled by viscoelastic 
relaxation of the matrix system during solvent penetration. This 
increase in the values of n may be attributed to the stronger 
hydrogen bonding between the carboxyl group on NaCMC and 
hydroxyl group on the nomomc gum, HPMC, leading to stronger 
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cross-linking between the two gums. The formulation composed of 
higher amount of NaCMC or HPMC exhibited lower value of n which 
represents the drug was released by Fickian diffusion, a first-order 
release, the diffusional pathlength for the drug increases with time. 
As shown in Figure 7, it illustrates that the detachment force 
required for separating tablet from stomach mucosa surface 
increased with increasing amount of NaCMC as the amount of EC in 
the formulation increased. This is due to the stronger bioadhesve 
capability provided by NaCMC. Tablets made with 180 mg NaCMC, 
40 mg HPMC, 90 mg EC and 30 mg polypladone XL will possess the 
best bioadhesive power. Figure 8 demonstrates the effect of two 
formulation variables on the required shear force. Again, as the 
amount of EC and NaCMC in the formulation increased, the required 
shear force for sliding tablet away from stomach mucosa was also 
increased. 
In Figure 9, the required compress10n force increased with 
increasing amount of NaCMC in the formulation as amount of EC 
increased. This is attributed to the poorer compactability of NaCMC 
and EC when compared to HPMC and polyplasdone XL. Formulation 
containing 40 mg N aCMC, 180 mg HPMC, 30 mg EC and 90 mg 
polyplasdone XL only requires 7 .5 KN compression force to produce 6 
Kg hardness tablets. The effect of four polymeric components on the 
tablet density was demonstrated in Figure 10, where it shows that 
tablet density increased with the increasing amount of NaCMC as EC 
increased. This is because of the higher bulk density of NaCMC and EC 
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when compared to HPMC and polyplasdone XL. Tablets made with 
50 mg NaCMC, 170 mg HPMC, 40 mg EC and 80 mg polyplasdone XL 
possessed a density lower than 1.0 resulted in no lag time m 
floatation process. These contour plots illustrate contour line of 
equal response and the direction in which the gradient has steeper 
values. 
Table XIV listed the optimum values of formulation variables for 
obtaining the best values of each of the response parameters. This 
Table was generated from the contour plots without placing any 
constraint on the response parameters. The optimum Xl and X2 
levels for obtaining the highest diffusional exponent value, n, are 109 
mg NaCMC/111 mg HPMC and 90 mg EC/ 30 mg polyplasdone XL 
while the optimum Xl and X2 levels for the minimum required 
compression force and tablet density are 40 mg N aCMC/180 mg 
HPMC and 30 mg EC/90 mg polyplasdone XL. In the case of 
detachment force, tablet formulation composed of 180 mg NaCMC, 40 
mg HPMC, 90 mg EC and 30 mg polyplasdone XL would require the 
highest force, 1.79 N for direct detachment. 
The dissolution release characteristic represented by the 
diffusional exponent value, n, was indentified as the pnmary 
response parameter because a zero-order release was desired for 
this extended sotalol tablet formulation. In addition, the in vitro 
dissolution usually provides an indication of in vivo bioavailability. 
The diffusional exponent n value was maximized so as to obtain a 
near zero-order release characteristic. As shown in Table XV, two 
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constraints were applied in obtaining the highest n value, the 
required compression force was constrained under 14 KN and the 
shear force was required to be more than 1.1 N. Additional 
constraints were the experimental range limits placed on values of 
two independent variables. The optimum fromulation satisfied all 
constraints simultaneously and provided an optimum value for the 
primary concern, the highest n value. 
The tablets were prepared on an instrumented B-2 rotary press 
according to the optimum formulation as shown in Table XIV, tablets 
properties were also determined. The comparison of predicted and 
experimental values for optimum formulation showed very good 
agreement and are shown in Table XVI. This reasonable prediction 
of the system's performance indicates the proposed model is valid. 
CONCLUSIONS 
A computer optimization process utililizing Response Surface 
Methodology (RSM) has been applied not only to develop and 
optimize a high dose acetaminophen-microcrystalline cellulose wet 
granulated tablet formulation exhibiting comparable physical tablets 
propreties (15) but also to develop and optimize a novel extended 
release sotalol HCl tablet formulation which possesses an unique 
combination of floatation and adhesion for prolonged residence in the 
stomach. The Box-Wilson experimental design was demonstrated to 
be an effective and efficient tool for the design, evaluation, and 
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optimization of a complex mixture for extended release with 
performance-related compositional constraints. Properties of the 
optimal formulation are very close approximation to the predicted 
profiles selected by surface response models. The optimized 240 mg 
sotalol HCl extended-release tablets showed a satisfactory dissolution 
profile, strong bioadhesive capability in terms of detachment force 
and shear force and excellent floatation characteristics (lag time of 
floatation < 8 minutes, duration time of floatation > 24 hours), and 
these tablets can be manufactured by an effficient and economical 
direct compression process. 
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TABLE I -- SUMMARY OF FORMULATION VARIABLES USED IN THE 
OPTIMIZATION PROCESS 
FORMULATION VARIABLES RANGE 
Xl : The ratio of NaCMC (mg) to HPMC (mg) l 1 /209 to 209/1 l 
X2 : The ratio of EC (mg) to Polyplasdone XL (mg) l 7. 6/102.4 to 102.4/17.6 
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TABLE II -- BOX-WILSON EXPERIMENT AL DESIGN FOR TWO FACTORS 
FACTORS : XI X2 
BATCH# 
l - I - l 
2 - I 
3 - I 
4 l 
5 - 1.414 0 
6 1.414 0 
7 0 - 1.414 
8 0 1.414 
9 0 0 
10 0 0 
l I 0 0 
12 0 0 
1 3 0 0 
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TABLE III --TRANSLATION OF EXPERIMENTAL CONDITIONS 
--------
- 1.414 - 1 0 I 1.414 
Factors: 
Xl=NaCMC(mg) I HPMC(mg) 11 /209 40/l 80 110/110 180/40 209/11 
eu*: 70 mg 
...... 
~ X2=EC(mg) I Polyplasdone(mg) 17.6/102.4 
°' 
30/90 60/60 90/30 102.4/17 .6 
eu*: 30 mg 
* eu: experimental unit 
TABLE IV -- RESPONSE PARAMETRS MEASURED IN THE OPTIMIZATION PROCEE 
RESPONSE PARAMETERS 
Y 1: Dissolution (Diffusional Exponent, n) 
Y2: Detachment Force (N) 
Y3: Shear Force (N) 
Y4: Required Compression Force (KN) for producing 6 Kg 
hardness tablets. 
Y5: Tablet Density (g/cm3) 
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TABLE V-- GENERAL QUADRATIC EQUATION: 
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TABLE VI. Diffusional exponent and mechanism of diffusional 
release from cylindrical swellable controlled release 
matrix system 
Diffusional exponent (n) 
< 0.45 
0.45 < n < 0.89 
0.89 
n > 0.89 
Drug release mechnism 
Fickian diffusion 
Anomalous (non-Fickian ) transport 
Case II transport 
Super Case II transport 
when the value of n = 0 .89 means that the drug release is 
independent of time , the release is characterized as zero-order 
release. 
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TABLE VII --- SUMMARY OF RESPONSE PARAMETERS 
Diffusional Detachment Shear Compression Density Lag Time 
Exponent, n Force(N) Force(N) Force( KN) (g/cm3) (minutes) 
----------------------------------
BATCH# 
1 0.40 1.0 0.637 10 .03 0 .979 0. 1 
2 0.38 1.372 0.882 16 .03 1.056 5 
3 0.50 1.390 1.078 10.46 1.036 7 
4 0.51 1.67 1.225 19 .37 1.077 8 
-Vl 5 0.42 1.26 0 .833 8.42 0 .997 0 .5 
0 
6 0.36 1.519 1.078 21.68 1.099 7 
7 0.54 1.25 1.029 11 .88 0.979 0. 1 
8 0.60 2. 107 1.666 15 .08 1.077 12 
9 0.58 1.127 1.372 13.46 1.056 8 
10 0 .59 l.201 1.354 13 .21 1.055 8 
l 1 0.58 l.131 1.298 12 .95 1.056 8.5 
12 0.59 1.135 l.342 13 .06 1.056 8 
13 0.59 l.126 1.364 H . 16 1.056 9 
------------------------- -----------
Range 0.36-0.60 1.0-2.107 0.637-1.666 8.42-21 .68 0 .979- 1.099 0 . I - 12 
TABLE VIII - Regression Coefficients for DENSITY 
-----------------------------------
-----------------------------------
Standard Confidence 
Coefficient Term Error T-Value Coef <> 0 
0.8550 1 (constant) 0.0212 40.37 99.9% 
0.000912 NACMC 0.0002 4.522 99.5% 
0.003261 ETHYLCELLULOSE 0.0005 6.339 99.8% 
-
-0.000004 NACMC*ETHYLCELLULOSE 0.0000 2.035 92.0% 
VI 
-0.000001 NACMCA2 0.0000 1.237 73.3% 
- -0.000016 ETHYLCELLULOSEA2 0.0000 4.218 99. 4% 
Confidence f i~ures are based on 7 degrees of freedom 
...... 
Ul 
N 
TABLE IX - Regression Coefficients for DETACHMENTFORCE 
------------ --- ------ -- --- -----------------
-------------------------------------------
Standard 
Coefficient Term Error T-Value 
1.484 
-0.001060 
-0.02065 
-0. 000011 
0.000016 
0.000248 
1 (constant) 
NACMC 
ETHYLCELLULOSE 
NACMC*ETHYLCELLULOSE 
NACMC.2 
ETHYLCELLULOSE.2 
Confidence figures are based on 7 degrees 
0.3009 4.932 
0.0029 0.3701 
0.0073 2.825 
0.0000 0.3660 
0.0000 1.652 
0.0001 4.685 
of freedom 
Confidence 
Coef <> 0 
99.6% 
31. 2% 
97.5% 
31. 0% 
85.6% 
99.6% 
-U\ 
Vl 
TABLE X - Regression Coefficients for SHEARFORCE 
Standard 
Coefficient Term Error 
-0.09344 1 (constant) 0.2594 
0.01299 NACMC 0.0025 
0.01474 ETHYLCELLULOSE 0.0063 
-0.000012 NACMC*ETHYLCELLULOSE 0.0000 
-0.000050 NACMc·2 0.0000 
-0.000054 ETHYLCELLULOSE.2 0.0000 
Confidence figures are based on 7 degrees of freedom 
Confidence 
T-Value Coef <> 0 
0.3602 30.7% 
5.259 99. 7% 
2.339 95.0% 
0.4522 35.2% 
5.946 99.8% 
l. l 7 5 70.9% 
TABLE XI - Regression Coefficients for COMPRESSIONFORCE 
Standard Confidence 
Coefficient Term Error T-Value Coef <> 0 
9.243 1 (constant) 1. 353 6.833 99.8% 
0.000360 NACMC 0.0129 0.0279 16.8% 
-0.01459 ETHYLCELLULOSE 0.0328 0.4442 34.8% 
-
0.000346 NACMC*ETHYLCELLULOSE 0.0001 2.575 96.4% 
VI 0.000177 NACMc·2 0.0000 4.051 99.3% 
.,i::. 0.000092 ETHYLCELLULOSE.2 0.0002 0.3869 32.0% 
Confidence figures are based on 7 degrees of freedom 
TABLE XII - Regression Coefficients for DENSITY 
-----------------------------------
-----------------------------------
Standard Confidence 
Coefficient Term Error T-Value Coef <> 0 
0.8550 1 (constant) 0.0212 40.37 99.9% 
-
0.000912 NACMC 0.0002 4.522 99.5% 
VI 0.003261 ETHYLCELLULOSE 0.0005 6.339 99.8% 
VI 
-0.000004 NACMC*ETHYLCELLULOSE 0.0000 2.035 92.0% 
-0.000001 NACMc·2 0.0000 l . 23 7 73.3% 
-0.000016 ETHYLCELLULOSEA2 0.0000 4.218 99. 4% 
Confidence f i~ures are based on 7 degrees of freedom 
TABLE XIII --REGRESSlON SUMMARY AND PREDlCTED RESPONSE 
PARAMETERS RANGES 
------------ ------------- F-Ratio ____ R_f __________ Predkted Val~~--
Regression Min . Max 
----------------------------------------------------------
Diffusional Exponent, n 23 . 17* 0 .95 0.61 0.37 
Detachment Force 11 .99* 0.90 1.02 l. 79 
Shear Force 14 .35* 0 .91 0 .726 1.51 
Compression Force 98 .75* 0.99 9 .6 20 . l 
Density 41.43 * 0 .97 0 .969 1.09 
* lmplies at least 99 % confidence regression equation is nonzero 
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TABLE XIV --- OPTIMUM VALUES OF FORMULATION VARIABLES TO 
OBTAIN BEST POSSIBLE RESPONSE PARAMETERS 
XI 
X2 
Diffusional 
Exponent, n 
Compression 
Detachment Force 
Shear force 
Density 
Diffusional 
Exponent, n 
105/115 
90/30 
Lil 
14 
1.6 
1.5 
1.07 
Detachment 
Force(N) 
180/40 
90/30 
0 .50 
20. l 
1...1.2 
1.33 
1.09 
Shear 
Force(N) 
120/100 
90/30 
0.61 
15 
1.62 
L..S.l 
1.07 
Compression Density 
Force( KN) 
40/180 40/180 
30/90 30/90 
0.44 0.44 
Ll 9.6 
1.06 1.06 
0 .726 0 .726 
0.969 0.969 
TABLE XV --CHOICE OF OPTIMUM FORMULATION 
Formulation Variable 
NaCMC/HPMC 
Ethylcellulose/Polyplasdone XL 
Constraints: 1. Compression Force< 14 KN 
2. Shear Force > 1.1 Newton 
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Value 
105/115 
90/3 0 
-Vl 
'° 
TABLE XVI --COMPARISON OF PREDICTED AND EXPERIMENTAL VALUES OF RESPONSE VARI ABLES 
FOR OJYflMUM FORMULATION 
Constraint 
Predicted 
Experimental 
Diffusional 
Exponent, n 
0.61 
0.62 
Detachment 
Force (N) 
1.6 
1.72 (0.21) 
* values in parenthesis represent standard deviation . 
She a r 
Force (N) 
>I.IN 
1.5 
1.4 (0.16) 
Compression 
Force (N) 
<14 KN 
14 
14.3 (0 .5) 
Density 
1.070 
1.064 (Cl.01) 
-----vertical rod fixing to the lnstron 
cubic vessel 
/ 
__ tablet detachment rod 
B ~ 
B 
membrane 
Fi qure 1. Apperetus for determi neti on of bi oedhesi veness of 
teblets; (A), Sliding Method, (B), Direct Detechment. 
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Figure 4· Dissolution profiles of sotalol 
tablet formulation batch# 7, 8 and 9 
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Figure S· Dissolution profiles of sotalol 
tablet formulation batch# 10, 11, 12 and 13 
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FIGURE 6 - EFFECT OF AMOUNT OF NaCMC AND EC ON 
THE DISSOLUTION (DIFFUSIONAL EXPONENT, n) 
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MANUSCRIPT V 
A NOVEL IN VITRO ASSESSMENT OF BIOADHESION OF 
VARIOUS ADHESIVE TABLET FORMULATIONS 
ABSTRACT 
An apparatus to be equipped with Instron tensile tester was 
developed to quantitatively evaluate the bioadhesive properties of 
various bioadhesive tablets. The equipment was designed to 
measure the forces required to separate two parallel surfaces (tablet 
and membrane) in both horizontal and vertical positions. In this 
work, in addition to the detachment force and adhesion work, the 
shear force necessary for separating bioadhesive tablet and synthetic 
membrane or biological tissue (rabbit stomach mucosa) were also 
determined since the majority of gastrointestinal mucosa surface 
area possesses some elements of tangential shear motion. The effects 
of different quantities and types of bioadhesive polymer on the 
tablet bioadhesive capability were also determined. The results 
showed good agreement with some previous findings that the 
relative adhesion of the tablet formulations was dependent on the 
bioadhesive polymer content. Tablet made with sodium 
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carboxymethycellulose (N aCMC) possessed the best bioadhesive 
power when compared to tablets made with polycarbophil and 
carbopol 97 4P. 
INTRODUCTION 
In the last decade, oral bioadhesive drug delivery systems have 
attracted considerable attention for localization and sustained release 
drug delivery, they are designed to prolong the gastrointestinal 
transit time of the dosage form and improve the bioavailability of 
drugs (1). 
The performance of a bioadhesive dosage form can be evaluated 
by various parameters, such as adhesion strength, adhesion number, 
and duration of adhesion. The measurement of mechanical 
properties of a bioadhesive system is the most direct way to quantify 
the bioadhesive properties. The tensile, shear and peel stress are 
more commonly used to quantify the adhesive force of contact joints. 
In tensile and shear loading, the stress is distributed uniformly over 
the entire joint. However, in peel loading, the stress is limited to a 
very fine line at the edge of the joint (2). 
Several in vitro techniques have been reported to determine the 
bioadhesion properties of bioadhesive oral dosage forms (3). The 
majority of these methods measure the tensile stress between the 
dosage form and the membranes or biological tissues ( 4-7). 
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However, the tensile stress provides only a partial reflection of 
mucoadhesion, since mucosa surface has some elements of a shear 
motion (5). 
In light of the above reason, an alternative technique was 
developed in this study to quantify the bioadhesiveness of selected 
oral dosage forms by measuring both detachment force and frictional 
force required to separate two paralell sufaces (tablet and 
membrane). 
Among vanous available bioadhesive polymers, sodium 
carboxymethylcellulose, polycarbophil and carbopol 974P are more 
commonly used in the oral bioadhesive dosage forms for both 
stronger bioadhesive power and lower toxicity reasons (8). In this 
study, the custom-designed apparatus was also utilized to classify 
tablets made with these three bioadhesive polymers in terms of 
detachment force, shear force as well as adhesion work. 
EXPERIMENTAL 
Preparation of the Bioadhesive Tablets 
Tablets free of drug were prepared in duplicate manner by 
mixing microcrystalline cellulose (Avicel PH 101, FMC Co., Lot 14361) 
and sodium carboxymethylcellulose (NaCMC 7MF, Aqualon Co., Lot 
67108), at four different propotions (12.5, 25, 50 and 75%) in a 
Turbular Mixer for 15 minutes, then compressing into tablets in a 
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Carver press. The final tablet has a weight of 500 mg and a hardness 
of 4.5 kg. 
Three batches of tablets made with NaCMC (7HF, Aqualon Co., Lot 
67798), Polycarbophil (Noveon AA 1, BFGoodrich Co., Lot X055009) 
and Carbopol 974P (BFGoodrich Co., Lot M710029), respectively, 
were also prepared by mixing 32.4% bioadhesive polymer, 32.4 % 
HPMC (Methocel Kl5M Premium CR Grade, Dow Co., Lot 
MM89011881K), 17.6 % ethylcellulose (Ethocel Premium V-10, Dow 
Co., Lot 6161187) and 17.6% crosspovidone NF (polyplasdone XL, 
GAF Chem. Co., Lot S01029) for 20 minutes, 3% of magnesium 
stearate (Fisher Scientific Co., Lot 742748) was then added as a 
lubricant and mixed for additional of 2 minutes before compress10n. 
Tablets were compressed m a B-2 rotary press with a weight of 662 
mg and a hardness of 6 Kg. 
Biological Tissues 
The biological tissue used was rabbit stomach mucosa. They were 
maintained in normal saline solution or used immmediately after the 
sacrifice of the animals. The stomach mucosa samples were 
immersed m normal saline solution and kept in the refrigerator at 5 
°C. These biological tissues were used in the comparison study of 
different types of bioadhesive polymer. 
Measurement of Bioadhesiveness 
Figure 1 shows the diagram of the custom-designed apparatus to 
be equipped with Instron Tensile Tester (lnstron, model 1122). The 
system consists of a small polyacrylic cylinder fastened to the side 
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wall of a polyacrylic cubic vessel to hold the membrane by means of 
an 0-ring. A retangular aluminum pieces with a hole in the middle 
was used as a support, to hold the tablet fixed over the surface of the 
membrane or biological tissues. The vessel was put on the lower 
plate of the Instron Tensile Tester , while the aluminum support was 
connected to the vertical rod and fixed to the upper clamp of the 
tensile tester. 
In a typical sliding adhesion test, after placing the tablet in the 
hole of the aluminum pieces, the membrane and tablet were brought 
together just to touch each other. The tablet and membrane surfaces 
were held parallel. The vessel was filled with constant volume of 
distilled water (1000 ml) at 22 C. After 30 minutes (pre-swelling 
time), the force was measured and recorded as a function of time 
until the tablet had crossed the membrane surface. Additionally, as 
can be seen from Figure 1, another polyacrylic cylinder is fixed to the 
bottom of the vessel to hold a membrane horizontally by means of an 
0-ring for the determination of direct detachment force. 
In the detachment force measurement, the tablet was stuck on to 
retangular aluminum support with a cyanoacrylate glue, the tablet 
support was fixed to the upper clamp of the tensile tester and 
lowered to maintain in a similar fashion that tablet and mucosa 
surfaces were rigorously parallel. The cubic vessel was filled with 
constant volume (1000ml) of pH 2 buffered solution at 22 C. After 
30 minutes, the crosspiece was raised at constant speed (20 
mm/min.) The detachment force was measured and recorded as a 
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function of displacement, up to the total separation of the tablet 
surface and tissue. The adhesion work was determined by 
calculating the area under the curve necessary for detachment. 
RESULTS AND DISCUSSION 
Figure 2 demonstrates a typical force versus time graph for one of 
the formulations studied. In general, the AB portion represents the 
early stage of the adhesion experiment, the force increased as a 
function of elongation. Point B represents the maximum adhesion 
force required to detach the tablet, the BC portion indicates the 
period where partial detachment of the bioadhesive tablet from the 
mucosa occured with slight decrease of the contact area. The portion 
CD of the curve describes the major change of the contact area due to 
the separation of the two surfaces. D point indicates the tablet was 
totally detached from the mucosa surface. 
Two parameters can be obtained from Figure 2 to analyze the 
adhesive characteristics of the tablets. The maximum adhesion force 
represented by point B, and the work of adhesion, determined by the 
area under the curve. Lejoyeux ~. (9) reported that this last 
parameter gives more interesting information concerning 
bioadhesion than the simple maximum detachment force. They also 
compared the adhesive capability of pure poly(acrylic acid) (PAA) 
tablets and pure hydroxypropylmethylcellulose (HPMC) tablets to 
bovine sublingual mucosa in liquid medium containing 100 g/l NaCl. 
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It showed there is no difference in detachment force measurement, 
however, in terms of adhesion work, PAA tablets were almost three 
time greater than HPMC tablets. 
The maximum shear force and adhesion work values measured at 
two different days with NaCMC tablets were summarized in Table I. 
No significant differences were observed in these two measurements 
for both parameters indicating the good reproducibility of this 
adhesion assessment apparatus. Figure 3 shows a linear relationship 
which was obtained when adhesion forces were plotted against 
polymer content for NaCMC tablets. As shown in Figure 4, a linear 
correlation also exists between the adhesion force and adhesion work 
for NaCMC tablets. These results show good agreement with some 
previous findings observed by Ishida et al.(10). They indicated that 
within the range of 0 to 30 % PAA, there was a linear relationship 
between the adhesive properties of white or hydrophilic petrolatum 
ointment and PAA contents. Hassan et al.(11) also showed that Nb 
values (viscosity component due to bioadhesion) was proportional to 
the PAA concentration m the bioadhesive system. Leung and 
Robinson (12) observed that the tensile stress of the PAA-mucin 
interaction decreased as the percent composition of acrylic acid 
decreased. Ponchel SiJ!l. (13) also reported a direct correlation 
between the work of adhesion and the quantity of the bioadhesive 
polymer, PAA, in the tablets. Meanwhile, Park (14) showed that the 
mucoadhesive property of copolymers of acrylic and acrylamide 
increased sharply until the acrylic acid content reached 70 %. 
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It is well known that the bioadhesiveness of certain polymers is 
very much dependent upon their ability to take up water from the 
medium immersed in, and thus become sticky and adhesive. The 
designed instrument would definitely satisfy the wetting condition 
necessary for such evaluations. Table II shows the comparison of 
work (energy) measured in dry and wet conditions. As is evident 
from this Table, the works measuerd in dry condition are almost 
constant for all tablets made with various polymer contents, while in 
the wet condition the works which are a total of adhesion and 
friction are different and propotional to the polymer content. 
Table III listed the bioadhesive characteristics of vanous tablets 
made with three different bioadhesive polymers. It indicates that 
tablets made with NaCMC possess the best bioadhesiveness among 
three different bioadhesive tablets in terms of detachment force, 
shear force and adhesion work. Tablets made with polycarbophil 
show similar detachment force and shear force but higher adhesion 
work when compared to tablets made with carbopol 974P. 
CONCLUSIONS 
The apparatus and technique designed for the determination of 
bioadhesion demonstrates good reproducibility, sensitivity and 
versatility (It can be tested either in dry or wet condition). The 
instrument enables one not only to determine both adhesional and 
frictional force but also to measure the adhesion work involved in 
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the whole separation process which is considered as an important 
indicator for bioadhesion power. 
The results show good agreement with some previous findings 
that the relative adhesion of bioadhesive solid dosage form was 
proportional to the bioadhesive polymers concentration. Meanwhile, 
bioadhesive tablets made with three different polymers all show 
excellent bioadhesion to stomach mucosa when N aCMC tablets 
exhibited the best bioadhesiveness. 
ACKNOWLEDGMENTS 
The authors are grateful to Dr. Chong M. Lee in the Department of 
Food Science, University of Rhode island for providing Instron 
Tensile Tester and valuable discussions. The financial support from 
Bristol-Myers Squibb is also greatly acknowledged. 
REEERENCES 
1. Gurny, R., Meyer, J.M. and Peppas, N.A., Biomaterials, 5, 336 
(1984). 
2. Park, K. and Park, H., Test methods of bioadhesion, In Lenaerts, 
V. and Gurny, R. (Eds.), Bioadhesive drug delivery systems, CRC 
Press, Boca Raton, pp. 43-64, 1990. 
178 
3. Duchene, D.,Touchard, F. and Peppas, N.A., Drug Dev. Ind. Pharm., 
14, 283 (1988). 
4. Al-Dujaili, H., Florence, A.T. and Salole, E.G., Int. J. Pharm., 34, 
75 (1986). 
5. Ishida, M., Machida, Y., Namba, N. and Nagai, T., Chem. Pharm. 
Bull., 29, 810 (1981). 
6. Forget, P., Gazzeri, P., Moreau, f., Sabatier, M., Durandeau, C., 
Merlet, J.P. and Aumonier, P., S.T.P. Pharma., 4,176 (1988). 
7. Lejoyeux, F., Ponchel, G., Wouessidjewe, D., Peppas, N.A. and 
Duchene, D., Drug Dev. Ind. Pharm., 15, 2037 (1989). 
8. Longer, M.A. and Robinson, J.R., Pharm. Int., 7, 114 (1987). 
9. Lejoyeux,F., Ponchel, G., Wouessidjewe, D., Peppas, N.A. and 
Duchene, D., 15 Proceed. Inter. Symp. Control. Rel. Bioact. 
Mater., Basel, pp. 348-349 (1988). 
10. Ishida, M., Nambu, N. and Nagai, T., Chem. Pharm. Bull., 31, 1010 
(1983). 
11 . Hassan, E.E. and Gallo, J.M., 16 Proceed. Intern. Symp. Control. 
Rel. Bioact. Mater., Chicago, pp. 414-415, (1989). 
12. Leung, S.H.S. and Robinson, J.R., J. Contr. Rel., 5, 223 (1988). 
13. Ponchel, G., Touchard, F., Duchene, D. and Peppas, N.A., J. 
Contr.Rel., 5, 129 (1987). 
14. Park, K., Int. J. Pharm., 53, 209 (1989). 
179 
TABLE I -- THE SHEAR FORCES AND ADHESION WORKS MEASURED AT TWO 
DIFFERENT DAYS WITH NaCMC TAB LETS 
% of NaCMC 
12.5 
25 
50 
75 
DAY 1 
Shear Force 
(Kg) 
0.181 (0. 012) 
0 .2 55 (0.008) 
0.555 (0 .057) 
0.828 (0.070) 
Work 
(Kg.mm) 
2. 7 4(0.49) 
3.35(0.38) 
4.89(0.24) 
5 .53(0.67) 
180 
DAY 2 
Shear Force 
(Kg) 
0 . 183 (0 .012) 
0.250(0 .036) 
0 .593(0.037) 
0 .8 06(0.050) 
Work 
(Kg.mm) 
2.98(0.13) 
3.62(0.30) 
4.68(0.53) 
6.30(0.41) 
TABLE II -- COMPARISON OF ADHESION WORK IN DRY AND WET CONDITIONS 
% of NaCMC 
12 .5 
25 
50 
75 
Work in dry condition 
(Kg.mm) 
1.81(0.52)* 
1.97(0.38) 
1.91(0.30) 
l.98(0.06) 
Work in water-preswollen 
condition (Kg.mm) 
2.74(0.49) 
3.35(0.38) 
4.89(0.24) 
5.53(0.67) 
* Values in parenthesis are standard deviations from three 
measurement. 
I 8 I 
TABLE III --COMPARISON OF VARIO US BIOADHESIVE TABLETS MADE WITH 
DIFFERENT BIOADHESIVE POLYMERS 
NaCMC 7HF Carbopol 974P Noveon-AAl 
Detachment Force(N) 1.23 (0.07 )* 0.83 (0.06) 0 .98 (0.05 ) 
Work ( mJ) 0.74 (0.14) 0.3 l (0. l 2) 0.45 (0 .14) 
Shear Force (N ) 1.37 (0.05 ) 0.34 (0 .04) 0.39 (0.05 ) 
Work( mJ) 11.04 (0.23 ) 3.92 (0.16) 5.33 (0.25 ) 
* Values in parenthesis are standard deviations from three 
measurements. 
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( Table I -- Direct Compression Sotalol HCl Tablet Formulation for 
Determining The Reproducibility 
(Three batches of sotalol tablets were manufactured at three 
different days with the same formulation ) 
Sotalol HCl 
NaCMC7HF 
HPMC K15MCR 
Ethyllcellulose V-10 
Polypladone XL 
Ca. Carbonate 
Mg. stearate 
Each Tablet (mg) 
240 
120 
120 
120 
20 
80 
2. 1 
Total Weight: 702.1 mg 
194 
Percentage 
34. 18 
17 .09 
17 .09 
17 .09 
2.85 
11.40 
0.30 
( 
Table II -- Properties of Three Batches of Sotalol Tablets 
Batches# 
1 2 3 
Weight, nu 701.11(1.59) 701.61(1.55) 701.70(1.27 ) 
Powder Flow Rate, g/sec. 16.7(1.2) 15.6(2.1) 16.1(1.7) 
Friability, % 0.26 0.29 0.30 
Thickness, Inch 0.2385 0.2385 0.2385 
Hardness, Kg_ 6.53(0.14 ) 6.6 5(0.22) 6.58(0.24) 
Compression Force, KN 15.40(0.33) 16.16(0.44) 15 .84(0.23) 
Lag Time to Float, Minutes 16.3(1.9) 16.0(1.1) 15.8(1.5) 
Content Uniformity, nu 235.8(3.2) 237.4(2.6) 236 .6(2.7) 
Values m parenthesis are standard deviations. 
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r Table III -- Dissolution Results of Three Batches Tablets 
Percentage of Drug Release 
Time (hours) Bat.#1 Bat.#2 Bat.#3 
0.5 15.94(1.57) 15.63(1.92) 15.16(2 .3 1) 
1 21.22(2.69) 23.17(2.50) 21.30(2.63) 
2 32.06(2.52) 32.41 (2.42) 31.25(2.69) 
4 47.98(1.97) 45.98(2.14) 45.07(3.33) 
6 59.94( 1.55) 57 .31(2.22) 55.76(4.04) 
8 69.25(3.18) 66 .69(2. 23) 64.82(3.39) 
1 2 82.24(3.02) 79 .42(2. 57) 77 .37(3.69) 
20 93 .52(2.60) 94.39(2.39) 91.83(3.47) 
24 96.30(1. 77) 98.20(2.66) 94.90(2.64) 
Values in parenthesis are standard deviations. 
196 
Table IV - Sotalol HCl Tablet Formulation for Determining The Effect 
of Different Grades of NaCMC on The Dissolution 
Ingredient (mg) 
Sotalol HCl 240 
NaCMC (7MF or 7HF) 120 
HPMC K15M 120 
EC VlO 120 
Polyplasdone XL 20 
Calcium carbonate 80 
Mg. stearate 2.1 
Total Weight: 702.1 mg 
197 
Table V - Sotalol HCl Tablet Formulation for Determining The Effect 
of Different Grades of HPMC on The Dissolution 
Ingredient (mg) 
Sotalol HCl 2 4 0 
NaCMC 7HF 1 2 0 
HPMC (K15M or K15M CR or KlOOM CR) 
EC VlO 
Polyplasdone XL 
Calcium Carbonate 
Mg. stearate 
120 
120 
20 
80 
2. 1 
Total Weight: 702.1 mg 
198 
Table VI - Sotalol HCl Tablet Formulaiton for Physical Stability Test 
(Tablets were stored at 40 C, 50 % relative humidity 
condition for one, two and three months) 
Ingredient (mg) 
Sotalol HCl 240 
NaCMC7HF 120 
HPMC KlOOM CR 120 
EC VlO 120 
Polyplasdone XL 20 
Calcium carbonate 80 
Mg. stearate 2. 1 
Total Weight: 702.1 mg 
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